Skip to main content
Psychedex
Sources
35
2 strong · 26 moderate · 7 weak

Studies and references cited across this article, graded by evidence strength.

Claims checked
95
64verified12partial19inconclusive

Inconclusive means the cited source neither confirms nor refutes the claim — a lower-confidence badge, not an error.

Generated
Apr 26, 2026 · pipeline-v5
Values approved
86/87 (99%)

Data points an editor reviewed and accepted for publication.

01

Value Provenance

Dosing

oraltrace

FieldPublishedAI ProposedConfidence
Threshold50 µg50 µglow
Low75–150 µg75–150 µglow
Common150–250 µg150–250 µglow
Strong250–400 µg250–400 µglow
Heavy400+ µg400+ µglow
Editorial

No controlled dose-response studies exist. Values derived from community consensus (existing database values in the 50-400+ µg range) which are consistent with the 0.5 mg (500 µg) pharmacologically effective dose documented by Huppertz et al. (2018) and the 0.5 mg dose producing 'strong sedation and amnesia' per Moosmann et al. (2015) and WHO ECDD (2020). The 0.5 mg documented dose falls at the boundary of strong/heavy tiers, supporting the overall range structure. These are community-consensus-derived breakpoints, not from controlled dose-escalation studies.

Reasoning

No controlled dose-response studies exist. Values derived from community consensus (existing database values in the 50-400+ µg range) which are consistent with the 0.5 mg (500 µg) pharmacologically effective dose documented by Huppertz et al. (2018) and the 0.5 mg dose producing 'strong sedation and amnesia' per Moosmann et al. (2015) and WHO ECDD (2020). The 0.5 mg documented dose falls at the boundary of strong/heavy tiers, supporting the overall range structure. These are community-consensus-derived breakpoints, not from controlled dose-escalation studies.

Evidence basis: community_consensus_large

Duration

oral

FieldPublishedAI ProposedConfidence
Onsettrace20–45 minutes20–45 minuteslow
Editorial

No controlled onset data. Estimated from community reports and class-level benzodiazepine pharmacology. The unusually long Tmax (~8h) from Huppertz et al. (2018) suggests slow absorption but initial effects likely appear earlier than peak.

Reasoning

No controlled onset data. Estimated from community reports and class-level benzodiazepine pharmacology. The unusually long Tmax (~8h) from Huppertz et al. (2018) suggests slow absorption but initial effects likely appear earlier than peak.

Evidence basis: community_consensus_large

Come uptrace45–90 minutes45–90 minuteslow
Editorial

Estimated from community reports. The gradual onset pattern is consistent with the prolonged Tmax.

Reasoning

Estimated from community reports. The gradual onset pattern is consistent with the prolonged Tmax.

Evidence basis: community_consensus_large

Peaktrace3–5 hours3–5 hourslow
Editorial

Estimated from community reports and the documented >10 hours of sedative effects at 0.5 mg (WHO ECDD 2020). Peak subjective intensity likely spans several hours given the long Tmax (~8h).

Reasoning

Estimated from community reports and the documented >10 hours of sedative effects at 0.5 mg (WHO ECDD 2020). Peak subjective intensity likely spans several hours given the long Tmax (~8h).

Evidence basis: community_consensus_large

Offsettrace3–6 hours3–6 hourslow
Editorial

Estimated from community reports and the 10-20h elimination half-life (Huppertz et al. 2018). Gradual offset consistent with slow elimination.

Reasoning

Estimated from community reports and the 10-20h elimination half-life (Huppertz et al. 2018). Gradual offset consistent with slow elimination.

Evidence basis: community_consensus_large

Totaltrace10–18 hours10–18 hourslow
Editorial

Existing database value of 12-18 hours total duration. WHO ECDD documented sedative effects >10 hours at 0.5 mg. The 10-20h half-life (Huppertz et al. 2018) supports subjective effects lasting 10-18 hours at common-to-strong doses. Lower bound adjusted to 10h to match WHO ECDD minimum documented effect duration.

Reasoning

Existing database value of 12-18 hours total duration. WHO ECDD documented sedative effects >10 hours at 0.5 mg. The 10-20h half-life (Huppertz et al. 2018) supports subjective effects lasting 10-18 hours at common-to-strong doses. Lower bound adjusted to 10h to match WHO ECDD minimum documented effect duration.

Evidence basis: community_consensus_large

After effectstrace12–48 hours12–48 hourslow
Editorial

Estimated from the long elimination half-life (10-20h) and documented residual impairment. Psychomotor impairment may persist well beyond subjective effects given the high volume of distribution and slow clearance (Noble et al. 2017). No controlled aftereffects data exist.

Reasoning

Estimated from the long elimination half-life (10-20h) and documented residual impairment. Psychomotor impairment may persist well beyond subjective effects given the high volume of distribution and slow clearance (Noble et al. 2017). No controlled aftereffects data exist.

Evidence basis: community_consensus_large

Safety

Toxicity Profiletrace

FieldPublishedAI ProposedConfidence
Acutehighhighmedium
Chronichighhighmedium
Organs Affectedcentral_nervous_system, respiratory, musculoskeletalcentral_nervous_system, respiratory, musculoskeletalmedium
Editorial

Classified as high acute risk: despite benzodiazepines' generally wide therapeutic index, flubromazolam's sub-milligram active dose range, documented coma/rhabdomyolysis case (Łukasik-Głębocka et al. 2016), presence in multiple fatality series (all polydrug), and drug supply contamination create functionally high acute danger. Chronic risk is high based on rapid tolerance development, severe withdrawal with seizure risk (Butler et al. 2025; WHO ECDD 2020), and absence of established equivalence dosing for clinical management. No LD50 data exist in any species.

Reasoning

Classified as high acute risk: despite benzodiazepines' generally wide therapeutic index, flubromazolam's sub-milligram active dose range, documented coma/rhabdomyolysis case (Łukasik-Głębocka et al. 2016), presence in multiple fatality series (all polydrug), and drug supply contamination create functionally high acute danger. Chronic risk is high based on rapid tolerance development, severe withdrawal with seizure risk (Butler et al. 2025; WHO ECDD 2020), and absence of established equivalence dosing for clinical management. No LD50 data exist in any species.

Evidence basis: published_case_series

Dependence Profiletrace

FieldPublishedAI ProposedConfidence
Physicalhighhighmedium
Psychologicalhighhighmedium
Compulsive Redosinghighhighmedium
Dose Escalationhighhighmedium
Editorial

WHO ECDD (2020) documented 'rapid onset of tolerance,' 'loss of control over use,' and severe withdrawal symptoms from online sources. Butler et al. (2025) reported seizure on abrupt cessation. Edinoff et al. (2022) documented 'severe withdrawals' in recreational users. All data from user reports and case reports — no formal dependence studies exist.

Reasoning

WHO ECDD (2020) documented 'rapid onset of tolerance,' 'loss of control over use,' and severe withdrawal symptoms from online sources. Butler et al. (2025) reported seizure on abrupt cessation. Edinoff et al. (2022) documented 'severe withdrawals' in recreational users. All data from user reports and case reports — no formal dependence studies exist.

Evidence basis: published_case_series

Withdrawal Profiletrace

FieldPublishedAI ProposedConfidence
Severitylife_threateninglife_threateninglow
Symptomsseizures, severe anxiety, panic attacks, muscle aches, sleep disturbances, dissociative symptoms, perceptual distortions, cramping, chills, vomitingseizures, severe anxiety, panic attacks, muscle aches, sleep disturbances, dissociative symptoms, perceptual distortions, cramping, chills, vomitinglow
FatalYesYeslow
Medical SupervisionRequiredRequiredlow
Editorial

Withdrawal symptoms documented by WHO ECDD (2020) from online sources. Seizure on abrupt cessation reported by Butler et al. (2025). Onset, peak, and total duration estimated from class-level benzodiazepine withdrawal kinetics scaled to flubromazolam's 10-20h half-life. Medical supervision required due to seizure risk and absence of established equivalence dosing for taper.

Reasoning

Withdrawal symptoms documented by WHO ECDD (2020) from online sources. Seizure on abrupt cessation reported by Butler et al. (2025). Onset, peak, and total duration estimated from class-level benzodiazepine withdrawal kinetics scaled to flubromazolam's 10-20h half-life. Medical supervision required due to seizure risk and absence of established equivalence dosing for taper.

Evidence basis: published_case_series

Tolerance Profiletrace

FieldPublishedAI ProposedConfidence
Builduprapidrapidlow
Half-life3.5 days3.5 dayslow
Full Reset10.5 days10.5 dayslow
Cross-tolerancesbenzodiazepines, alcohol, barbiturates, z-drugs, gabapentinoidsbenzodiazepines, alcohol, barbiturates, z-drugs, gabapentinoidslow
Editorial

WHO ECDD (2020) documented 'rapid onset of tolerance' from online reports. Edinoff et al. (2022) confirmed 'rapid development of tolerance.' Molecular mechanism from Navarrete et al. (2026) and Figg et al. (2026) — class-level benzodiazepine tolerance mechanisms. Reset timeline extrapolated from elimination half-life and general benzodiazepine pharmacology, not from substance-specific data.

Reasoning

WHO ECDD (2020) documented 'rapid onset of tolerance' from online reports. Edinoff et al. (2022) confirmed 'rapid development of tolerance.' Molecular mechanism from Navarrete et al. (2026) and Figg et al. (2026) — class-level benzodiazepine tolerance mechanisms. Reset timeline extrapolated from elimination half-life and general benzodiazepine pharmacology, not from substance-specific data.

Evidence basis: community_consensus_large

Effects & Profile

Contraindications

FieldPublishedAI ProposedConfidence
respiratory opioid co-usetraceabsoluteabsolutehigh
Editorial

FDA black box warning for all opioid+BZD combinations (Figg et al. 2026). Mechanistic basis from Horsfall & Sprague (2017) and Xu et al. (2020). Epidemiological data from Liu et al. (2021) MMWR. Drug supply contamination from Laing et al. (2021).

Reasoning

FDA black box warning for all opioid+BZD combinations (Figg et al. 2026). Mechanistic basis from Horsfall & Sprague (2017) and Xu et al. (2020). Epidemiological data from Liu et al. (2021) MMWR. Drug supply contamination from Laing et al. (2021).

respiratory alcohol co-usetraceabsoluteabsolutehigh
Editorial

Documented in polydrug death cases (Drummer et al. 2024). Class-level benzodiazepine-alcohol interaction.

Reasoning

Documented in polydrug death cases (Drummer et al. 2024). Class-level benzodiazepine-alcohol interaction.

respiratory other CNS depressant co-usetraceabsoluteabsolutehigh
Editorial

Documented polydrug death patterns (Hikin et al. 2024; Drummer et al. 2024). Class-level pharmacology.

Reasoning

Documented polydrug death patterns (Hikin et al. 2024; Drummer et al. 2024). Class-level pharmacology.

other CYP3A4 inhibitor co-administrationtracerelativerelativemedium
Editorial

CYP3A4/5 identified as primary metabolic pathway by Noble et al. (2017). Mechanistic inference only.

Reasoning

CYP3A4/5 identified as primary metabolic pathway by Noble et al. (2017). Mechanistic inference only.

pregnancy breastfeeding pregnancy and breastfeedingtraceabsoluteabsolutemedium
Editorial

Class-level benzodiazepine contraindication (Figg et al. 2026). No substance-specific data.

Reasoning

Class-level benzodiazepine contraindication (Figg et al. 2026). No substance-specific data.

neurological epilepsytracerelativerelativemedium
Editorial

Seizure on abrupt cessation documented by Butler et al. (2025). Class-level withdrawal seizure risk from WHO ECDD (2020).

Reasoning

Seizure on abrupt cessation documented by Butler et al. (2025). Class-level withdrawal seizure risk from WHO ECDD (2020).

other benzodiazepine hypersensitivitytraceabsoluteabsolutehigh
Editorial

Class-level contraindication for all benzodiazepines.

Reasoning

Class-level contraindication for all benzodiazepines.

Timeline Phases

oral

FieldPublishedAI ProposedConfidence
Onsettrace1200–2700 sec(i=0.05)1200–2700 sec(i=0.05)low
Editorial

Timeline derived from: (1) single self-experiment showing Tmax ~8h, half-life 10-20h, sedative effects >10h at 0.5 mg (Huppertz et al. 2018; WHO ECDD 2020), (2) community-reported total duration of 12-18 hours from existing database, (3) class-level benzodiazepine pharmacology. No controlled time-course studies exist. The unusually long Tmax differentiates flubromazolam's timeline from most benzodiazepines.

Reasoning

Timeline derived from: (1) single self-experiment showing Tmax ~8h, half-life 10-20h, sedative effects >10h at 0.5 mg (Huppertz et al. 2018; WHO ECDD 2020), (2) community-reported total duration of 12-18 hours from existing database, (3) class-level benzodiazepine pharmacology. No controlled time-course studies exist. The unusually long Tmax differentiates flubromazolam's timeline from most benzodiazepines.

Come uptrace2700–5400 sec(i=0.30)2700–5400 sec(i=0.30)low
Editorial

Timeline derived from: (1) single self-experiment showing Tmax ~8h, half-life 10-20h, sedative effects >10h at 0.5 mg (Huppertz et al. 2018; WHO ECDD 2020), (2) community-reported total duration of 12-18 hours from existing database, (3) class-level benzodiazepine pharmacology. No controlled time-course studies exist. The unusually long Tmax differentiates flubromazolam's timeline from most benzodiazepines.

Reasoning

Timeline derived from: (1) single self-experiment showing Tmax ~8h, half-life 10-20h, sedative effects >10h at 0.5 mg (Huppertz et al. 2018; WHO ECDD 2020), (2) community-reported total duration of 12-18 hours from existing database, (3) class-level benzodiazepine pharmacology. No controlled time-course studies exist. The unusually long Tmax differentiates flubromazolam's timeline from most benzodiazepines.

Peaktrace10800–18000 sec(i=1.00)10800–18000 sec(i=1.00)low
Editorial

Timeline derived from: (1) single self-experiment showing Tmax ~8h, half-life 10-20h, sedative effects >10h at 0.5 mg (Huppertz et al. 2018; WHO ECDD 2020), (2) community-reported total duration of 12-18 hours from existing database, (3) class-level benzodiazepine pharmacology. No controlled time-course studies exist. The unusually long Tmax differentiates flubromazolam's timeline from most benzodiazepines.

Reasoning

Timeline derived from: (1) single self-experiment showing Tmax ~8h, half-life 10-20h, sedative effects >10h at 0.5 mg (Huppertz et al. 2018; WHO ECDD 2020), (2) community-reported total duration of 12-18 hours from existing database, (3) class-level benzodiazepine pharmacology. No controlled time-course studies exist. The unusually long Tmax differentiates flubromazolam's timeline from most benzodiazepines.

Plateautrace7200–14400 sec(i=0.50)7200–14400 sec(i=0.50)low
Editorial

Timeline derived from: (1) single self-experiment showing Tmax ~8h, half-life 10-20h, sedative effects >10h at 0.5 mg (Huppertz et al. 2018; WHO ECDD 2020), (2) community-reported total duration of 12-18 hours from existing database, (3) class-level benzodiazepine pharmacology. No controlled time-course studies exist. The unusually long Tmax differentiates flubromazolam's timeline from most benzodiazepines.

Reasoning

Timeline derived from: (1) single self-experiment showing Tmax ~8h, half-life 10-20h, sedative effects >10h at 0.5 mg (Huppertz et al. 2018; WHO ECDD 2020), (2) community-reported total duration of 12-18 hours from existing database, (3) class-level benzodiazepine pharmacology. No controlled time-course studies exist. The unusually long Tmax differentiates flubromazolam's timeline from most benzodiazepines.

Resolutiontrace5400–10800 sec(i=0.20)5400–10800 sec(i=0.20)low
Editorial

Timeline derived from: (1) single self-experiment showing Tmax ~8h, half-life 10-20h, sedative effects >10h at 0.5 mg (Huppertz et al. 2018; WHO ECDD 2020), (2) community-reported total duration of 12-18 hours from existing database, (3) class-level benzodiazepine pharmacology. No controlled time-course studies exist. The unusually long Tmax differentiates flubromazolam's timeline from most benzodiazepines.

Reasoning

Timeline derived from: (1) single self-experiment showing Tmax ~8h, half-life 10-20h, sedative effects >10h at 0.5 mg (Huppertz et al. 2018; WHO ECDD 2020), (2) community-reported total duration of 12-18 hours from existing database, (3) class-level benzodiazepine pharmacology. No controlled time-course studies exist. The unusually long Tmax differentiates flubromazolam's timeline from most benzodiazepines.

Afterglowtrace28800–86400 sec(i=0.05)28800–86400 sec(i=0.05)low
Editorial

Timeline derived from: (1) single self-experiment showing Tmax ~8h, half-life 10-20h, sedative effects >10h at 0.5 mg (Huppertz et al. 2018; WHO ECDD 2020), (2) community-reported total duration of 12-18 hours from existing database, (3) class-level benzodiazepine pharmacology. No controlled time-course studies exist. The unusually long Tmax differentiates flubromazolam's timeline from most benzodiazepines.

Reasoning

Timeline derived from: (1) single self-experiment showing Tmax ~8h, half-life 10-20h, sedative effects >10h at 0.5 mg (Huppertz et al. 2018; WHO ECDD 2020), (2) community-reported total duration of 12-18 hours from existing database, (3) class-level benzodiazepine pharmacology. No controlled time-course studies exist. The unusually long Tmax differentiates flubromazolam's timeline from most benzodiazepines.

Dose Tier Summaries

thresholdtrace
low

At threshold doses (~50 µg oral), effects are subtle and may be indistinguishable from placebo in naive users. A mild sense of relaxation and slight reduction in background anxiety may be perceptible. Some users report a faint heaviness in the limbs and minimal mood elevation. Physical effects are generally sub-perceptual at this range. Slight muscle relaxation may be noticeable to attentive users. Cognitive function remains largely intact, though very mild thought deceleration is possible. Functional impairment is minimal but not absent — driving and precision tasks should be avoided. Duration of noticeable effects at threshold doses is shorter than at higher doses, typically 4–8 hours.

Editorial

No controlled dose-response studies exist. Threshold value inferred from community-derived dose ranges consistent with the 0.5 mg pharmacologically effective dose documented by Huppertz et al. (2018) and Moosmann et al. (2015). Threshold is approximately 10% of the documented effective dose.

Reasoning

No controlled dose-response studies exist. Threshold value inferred from community-derived dose ranges consistent with the 0.5 mg pharmacologically effective dose documented by Huppertz et al. (2018) and Moosmann et al. (2015). Threshold is approximately 10% of the documented effective dose.

Evidence basis: community_consensus_large

lighttrace
low

At light doses (75–150 µg oral), anxiolysis becomes clearly perceptible — a noticeable reduction in anxiety and social tension. Mild sedation emerges, along with a gentle sense of well-being and emotional blunting. Thought deceleration is apparent but manageable. Muscle relaxation becomes more distinct. Motor coordination is mildly impaired — fine motor tasks may feel clumsy. Mild appetite changes and slight drowsiness are common. Cognitive function is noticeably dulled but basic tasks remain possible. Memory formation begins to be affected — minor gaps in recall may appear. Effects typically last 6–10 hours. Functional impairment is present and incompatible with driving or operating machinery.

Editorial

No controlled dose-response data. Light dose range derived from community consensus consistent with sub-milligram activity documented in the literature. The 0.5 mg dose produced 'strong sedation' per WHO ECDD, placing light effects well below that threshold.

Reasoning

No controlled dose-response data. Light dose range derived from community consensus consistent with sub-milligram activity documented in the literature. The 0.5 mg dose produced 'strong sedation' per WHO ECDD, placing light effects well below that threshold.

Evidence basis: community_consensus_large

commontrace
low

At common doses (150–250 µg oral), the characteristic flubromazolam profile fully manifests: pronounced sedation, significant anxiolysis, and clear muscle relaxation. Euphoria is frequently reported at this range. Emotional responses are blunted and social inhibitions markedly reduced. Disinhibition and increased talkativeness may occur. Physically, motor impairment becomes substantial — coordination is visibly affected and gait may become unsteady. Slurred speech is possible. Drowsiness is prominent and many users will fall asleep during the experience. Anterograde amnesia becomes a significant feature at this range — users may have incomplete or absent recall of events during the experience. Thought deceleration and disorganisation are pronounced. The risk of compulsive redosing is elevated due to delusions of sobriety. Total duration typically spans 10–14 hours with residual impairment persisting well beyond subjective effects.

Editorial

Community-derived dose ranges. The documented 0.5 mg dose producing strong sedation exceeding 10 hours and amnesia exceeding 24 hours (WHO ECDD 2020) falls at the upper end of this range, supporting the characterisation of common-dose effects.

Reasoning

Community-derived dose ranges. The documented 0.5 mg dose producing strong sedation exceeding 10 hours and amnesia exceeding 24 hours (WHO ECDD 2020) falls at the upper end of this range, supporting the characterisation of common-dose effects.

Evidence basis: community_consensus_large

strongtrace
low

At strong doses (250–400 µg oral), heavy sedation dominates the experience. Users report extreme drowsiness, profound muscle relaxation, and marked euphoria before sedation overtakes the experience. Loss of consciousness or near-unconscious states are common. Behavioural disinhibition may be extreme in the period before sleep onset. Motor impairment is severe — walking is difficult or impossible. Speech is heavily slurred. Physical coordination is profoundly compromised. Anterograde amnesia is near-total at this range, often extending well beyond 24 hours. The documented single-dose amnesia exceeding 24 hours at 0.5 mg corresponds to the upper portion of this tier. Compulsive redosing risk is very high due to complete inability to assess one's own intoxication. Total duration extends to 12–18 hours with aftereffects persisting 24–48 hours.

Editorial

Upper portion of this range overlaps with the documented 0.5 mg dose producing >10 hours sedation and >24 hours amnesia (WHO ECDD 2020; Huppertz et al. 2018). Strong tier represents approaching the boundary of documented pharmacological effects.

Reasoning

Upper portion of this range overlaps with the documented 0.5 mg dose producing >10 hours sedation and >24 hours amnesia (WHO ECDD 2020; Huppertz et al. 2018). Strong tier represents approaching the boundary of documented pharmacological effects.

Evidence basis: community_consensus_large

heavytrace
low

At heavy doses (above 400 µg oral), the experience is dominated by loss of consciousness, profound and extended amnesia, and severe psychomotor incapacitation. Users typically have no memory of the experience. Blackout states lasting many hours are characteristic. Physically, the risk of respiratory depression is elevated, particularly in combination with any other CNS depressant. Hypotension and rhabdomyolysis have been documented in case reports at this exposure level. The risk of aspiration during unconsciousness is clinically significant. Recovery is prolonged — residual sedation, cognitive impairment, and amnesia may persist for 24–72 hours. The boundary between heavy recreational use and medical emergency is indistinct at this range. Compulsive redosing during amnestic states can escalate exposure to dangerous levels without the user's awareness.

Editorial

The first published case report (Łukasik-Głębocka et al. 2016) described severe intoxication with coma, hypotension, and rhabdomyolysis, consistent with effects at or above this range. No controlled dose-response data exist; values are community-derived with pharmacological plausibility from case reports.

Reasoning

The first published case report (Łukasik-Głębocka et al. 2016) described severe intoxication with coma, hypotension, and rhabdomyolysis, consistent with effects at or above this range. No controlled dose-response data exist; values are community-derived with pharmacological plausibility from case reports.

Evidence basis: community_consensus_large

02

History

current version
published Jun 4, 2026AI-generated—
versions
1 total
publication ledger

backfill Jun 4, 2026

Historical versions do not record which reviewer approved them; editorial accountability is recorded per value in the database and in the publication ledger going forward.

full version history suggest a correctioncontact@psychedex.org
03

Sources

2 strong · 26 moderate · 7 weak
  1. [1]
    moderate
    The use of a quantitative structure-activity relationship (QSAR) model to predict GABA-A receptor binding of newly emerging benzodiazepines
    Waters LJ, Manchester KR, Maskell P, Haegeman C, Haider S · 2017 · Science & Justice
    doi.org/10.1016/j.scijus.2017.12.0043 claims checked3 verified
  2. [2]
    moderate
    Structural and dynamic mechanisms of GABAA receptor modulators with opposing activities
    Zhu S, Sridhar A, Teng J, Howard RJ, Lindahl E, Hibbs RE · 2022 · Nature Communications
    doi.org/10.1038/s41467-022-32212-4pubmed 359334263 claims checked3 verified
  3. [3]
    weak
    Critical Review Report: FLUBROMAZOLAM
    WHO Expert Committee on Drug Dependence (43rd ECDD) · 2020
    linkno claims checked
  4. [4]
    moderate
    Flubromazolam - Basic pharmacokinetic evaluation of a highly potent designer benzodiazepine
    Huppertz LM, Moosmann B, Auwärter V · 2018 · Drug Testing and Analysis
    doi.org/10.1002/dta.2203pubmed 2837853314 claims checked9 verified2 partial3 inconclusive
  5. [5]
    moderate
    Designer benzodiazepines: A new challenge
    Moosmann B, King LA, Auwärter V · 2015 · World Psychiatry
    doi.org/10.1002/wps.20236pubmed 260433479 claims checked4 verified4 partial1 inconclusive
  6. [6]
    weak
    Schedules of Controlled Substances: Placement of Clonazolam, Diclazepam, Etizolam, Flualprazolam, and Flubromazolam in Schedule I of the Controlled Substances Act
    Drug Enforcement Administration, US Department of Justice · 2026
    linkno claims checked
  7. [7]
    weak
    Successful symptom-based management of active withdrawal from multiple illicit benzodiazepines
    Butler M, Pirkle J, Carmichael A, Carlson-Dexter P, Rosella T · 2025 · BMJ Case Reports
    doi.org/10.1136/bcr-2025-266077pubmed 407594956 claims checked4 verified2 inconclusive
  8. [8]
    moderate
    Trends in Nonfatal and Fatal Overdoses Involving Benzodiazepines - 38 States and the District of Columbia, 2019-2020
    Liu S, O'Donnell J, Gladden RM, McGlone L, Chowdhury F · 2021 · MMWR Morbidity and Mortality Weekly Report
    doi.org/10.15585/mmwr.mm7034a2pubmed 344375224 claims checked3 verified1 partial
  9. [9]
    moderate
    Benzodiazepine Dependence: Clinical and Molecular Aspects, Preventive Strategies and Therapeutic Approaches.
    Navarrete F, Marín-Mayor M, Martínez-Hostyn L, Rubio G, Manzanares J · 2026 · International journal of molecular sciences
    doi.org/10.3390/ijms27031430pubmed 416838523 claims checked2 verified1 partial
  10. [10]
    moderate
    Characterization of the four designer benzodiazepines clonazolam, deschloroetizolam, flubromazolam, and meclonazepam, and identification of their in vitro metabolites
    Huppertz LM, Bisel P, Westphal F, Franz F, Auwärter V, Moosmann B · 2015 · Forensic Toxicology
    doi.org/10.1007/s11419-015-0277-62 claims checked2 inconclusive
  11. [11]
    moderate
    The Emergence of Novel Benzodiazepines in Australia, Evidence, Alerts, Clinical Management and Harm Reduction - A Narrative Review
    Freestone J, Kypri S, Schumann JL, et al. · 2026 · Drug and Alcohol Review
    doi.org/10.1111/dar.70086pubmed 413541341 claim checked1 inconclusive
  12. [12]
    weak
    Flubromazolam – A new life-threatening designer benzodiazepine
    Łukasik-Głębocka M, Sommerfeld K, Tężyk A, Zielińska-Psuja B, Panieński P, Żaba C · 2016 · Clinical Toxicology
    doi.org/10.3109/15563650.2015.1112907pubmed 265855573 claims checked3 verified
  13. [13]
    weak
    Schedules of Controlled Substances: Temporary Placement of Etizolam, Flualprazolam, Clonazolam, Flubromazolam, and Diclazepam in Schedule I
    Drug Enforcement Administration, US Department of Justice · 2023
    linkno claims checked
  14. [14]
    moderate
    Novel Designer Benzodiazepines: Comprehensive Review of Evolving Clinical and Adverse Effects
    Edinoff AN, Nix CA, Odisho AS, Babin CP, Derouen AG, Lutfallah SC, Cornett EM, Murnane KS, Kaye AM, Kaye AD · 2022 · Neurology International
    doi.org/10.3390/neurolint14030053pubmed 359973627 claims checked3 verified4 inconclusive
  15. [15]
    moderate
    In vitro studies on flubromazolam metabolism and detection of its metabolites in authentic forensic samples
    Noble C, Mardal M, Bjerre Holm N, Stybe Johansen S, Linnet K · 2017 · Drug Testing and Analysis
    doi.org/10.1002/dta.2146pubmed 279352607 claims checked7 verified
  16. [16]
    moderate
    Benzodiazepines at the crossroads: navigating therapeutic promise and perils of misuse
    Figg JW, Love CA, Sorathia V, Engelbart M, Turner A, Elton A · 2026 · Annals of General Psychiatry
    doi.org/10.1186/s12991-025-00627-0pubmed 416221846 claims checked3 verified3 inconclusive
  17. [17]
    moderate
    The Pharmacology and Toxicology of the 'Holy Trinity'
    Horsfall JT, Sprague JE · 2017 · Basic & Clinical Pharmacology & Toxicology
    doi.org/10.1111/bcpt.12655pubmed 275501521 claim checked1 verified
  18. [18]
    moderate
    Developing an animal model to detect drug-drug interactions impacting drug-induced respiratory depression
    Xu L, Chockalingam A, Stewart S, et al. · 2020 · Toxicology Reports
    doi.org/10.1016/j.toxrep.2020.01.008pubmed 320218082 claims checked2 verified
  19. [19]
    moderate
    Designer benzodiazepine rat pharmacokinetics: A comparison of alprazolam, flualprazolam and flubromazolam
    Canfield JR, Kisor DF, Sprague JE · 2023 · Toxicology and Applied Pharmacology
    doi.org/10.1016/j.taap.2023.116459pubmed 369073832 claims checked1 verified1 partial
  20. [20]
    moderate
    Detectability of designer benzodiazepines in CEDIA, EMIT II Plus, HEIA, and KIMS II immunochemical screening assays
    Pettersson Bergstrand M, Helander A, Hansson T, Beck O · 2017 · Drug Testing and Analysis
    doi.org/10.1002/dta.2003pubmed 273668701 claim checked1 verified
  21. [21]
    moderate
    Recent findings and advancements in the detection of designer benzodiazepines: a brief review
    Wu D, Fu L · 2022 · Arhiv za higijenu rada i toksikologiju
    doi.org/10.2478/aiht-2023-74-3771pubmed 381467631 claim checked1 verified
  22. [22]
    moderate
    Fast and Sensitive Method for the Determination of 17 Designer Benzodiazepines in Hair by Liquid Chromatography-Tandem Mass Spectrometry
    DeFreitas L, Fonseca Pego AM, Kronstrand R, Lendoiro E, de Castro-Rios A, Concheiro M · 2022 · Journal of Analytical Toxicology
    doi.org/10.1093/jat/bkac044pubmed 357488141 claim checked1 verified
  23. [23]
    moderate
    An outbreak of novel psychoactive substance benzodiazepines in the unregulated drug supply: Preliminary results from a community drug checking program
    Laing MK, Ti L, Marmel A, Tobias S, Shapiro AM, Laing R, Lysyshyn M, Socias ME · 2021 · International Journal on Drug Policy
    doi.org/10.1016/j.drugpo.2021.103169pubmed 336273023 claims checked1 verified1 partial1 inconclusive
  24. [24]
    weak
    Multiple Drug-Toxicity Involving Novel Psychoactive Substances, 3-Fluorophenmetrazine and U-47700
    Ellefsen KN, Taylor EA, Simmons P, Willoughby V, Hall BJ · 2017 · Journal of Analytical Toxicology
    doi.org/10.1093/jat/bkx060pubmed 289853201 claim checked1 verified
  25. [25]
    moderate
    Designer Benzodiazepines: A Review of Toxicology and Public Health Risks
    Brunetti P, Giorgetti R, Tagliabracci A, Huestis MA, Busardò FP · 2021 · Pharmaceuticals
    doi.org/10.3390/ph14060560pubmed 342082841 claim checked1 verified
  26. [26]
    moderate
    Increasing prevalence of designer benzodiazepines in impaired driving: A 5-year analysis from 2017 to 2021
    Papsun DM, Chan-Hosokawa A, Lamb ME, Logan B · 2023 · Journal of Analytical Toxicology
    doi.org/10.1093/jat/bkad036pubmed 373381913 claims checked2 verified1 inconclusive
  27. [27]
    moderate
    The Evolution Toward Designer Benzodiazepines in Drug-Facilitated Sexual Assault Cases
    Pérez Orts M, van Asten A, Köhler I · 2023 · Journal of Analytical Toxicology
    doi.org/10.1093/jat/bkac017pubmed 352940221 claim checked1 verified
  28. [28]
    moderate
    Deaths involving novel benzodiazepines in Victoria, Australia from 2018 to 2022
    Drummer OH, Joubert S, Di Rago M, Castle JW, Crump K, Glowacki L, Gerostamoulos D · 2024 · Journal of Analytical Toxicology
    doi.org/10.1093/jat/bkae075pubmed 391905582 claims checked2 verified
  29. [29]
    weak
    Suspected North Carolina counterfeit pill-involved deaths, 2020-2022
    Friederich LW, Cox ME, Hyson BE, Bishop-Freeman SC · 2024 · Journal of Analytical Toxicology
    doi.org/10.1093/jat/bkae027pubmed 386764142 claims checked2 verified
  30. [30]
    moderate
    'New/Designer Benzodiazepines': An Analysis of the Literature and Psychonauts' Trip Reports
    Orsolini L, Corkery JM, Chiappini S, Guirguis A, Vento A, et al. · 2020 · Current Neuropharmacology
    doi.org/10.2174/1570159x18666200110121333pubmed 319334431 claim checked1 inconclusive
  31. [31]
    moderate
    Post mortem blood bromazolam concentrations and co-findings in 96 coronial cases within England and Wales
    Hikin LJ, Coombes G, Rice-Davies K, Couchman L, Smith PR, Morley SR · 2024 · Forensic Science International
    doi.org/10.1016/j.forsciint.2023.111891pubmed 380434982 claims checked2 partial
  32. [32]
    moderate
    Flubromazolam-Derived Designer Benzodiazepines: Toxicokinetics and Analytical Toxicology of Clobromazolam and Bromazolam
    Wagmann L, Manier SK, Felske C, Gampfer TM, Richter MJ, Eckstein N, Meyer MR · 2021 · Journal of Analytical Toxicology
    doi.org/10.1093/jat/bkaa161pubmed 33048135no claims checked
  33. [33]
    strong
    Adverse Events Associated with Flumazenil Treatment for the Management of Suspected Benzodiazepine Intoxication--A Systematic Review with Meta-Analyses.
    Penninga EI, Graudal N, Ladekarl MB, Jürgens G · 2016 · Basic & clinical pharmacology & toxicology
    doi.org/10.1111/bcpt.12434pubmed 260963141 claim checked1 verified
  34. [34]
    moderate
    The surge of bromazolam-related fatalities replacing other novel designer benzodiazepines-related fatalities in San Francisco
    Rodda LN · 2024 · Addiction
    doi.org/10.1111/add.16520pubmed 386798681 claim checked1 verified
  35. [35]
    strong
    Could Flumazenil Be Used Pre-hospital by Intramuscular Injection for Coma due to Mixed Drug Overdose Not Responding to Naloxone?: A Systematic Review
    Farcas I, Schölin L, Eddleston M · 2025 · Basic & Clinical Pharmacology & Toxicology
    doi.org/10.1111/bcpt.70007pubmed 399490491 claim checked1 verified
04

Claim Verification

Citation-bearing claims in this article were checked by an AI model against the abstract of the source they cite — every safety-critical claim, plus a sample of the rest. Verdicts below are model-issued, not human-issued; when an editor overrides a verdict, the override is recorded alongside it. Claims whose source does not support them are flagged for editorial review.

summary9 claims7verified2partial
verifiedThe terminal elimination half-life is estimated at 10–20 hours.[4]model confidence 99%
Verified

Abstract explicitly states 'terminal elimination half-life 10-20h' from the self-experiment.

terminal elimination half-life 10-20h

checked by claude-sonnet-4-6 · Apr 26, 2026

partialIt appeared on online research chemical markets from 2014 and was rapidly flagged as a public health concern due to sub-milligram active doses that are difficult to measure accurately in unregulated preparations[4]model confidence 75%
Partial

Abstract confirms 2014 online appearance, but does not address being 'rapidly flagged as a public health concern' or 'difficult to measure in unregulated preparations' — these are not in a PK paper.

Flubromazolam offered online from 2014

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedIt appeared on online research chemical markets from 2014 and was rapidly flagged as a public health concern due to sub-milligram active doses that are difficult to measure accurately in unregulated preparations[5]model confidence 85%
Verified

Abstract is a public health letter identifying flubromazolam at sub-milligram doses (0.5 mg) as a concern, noting detection and scheduling challenges. 'Difficult to measure' is implicit in the context of a high-potency compound with such challenges.

compounds like clonazolam or flubromazolam can cause strong sedation and amnesia at oral doses as low as 0.5 mg. Notes challenges with immunochemical detection and legal scheduling.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedThe entire published human pharmacokinetic dataset derives from a single researcher self-experiment.[4]model confidence 92%
Verified

Abstract describes the study as a self-experiment, and the SCOPE confirms it is 'only published human pharmacokinetic data for flubromazolam.'

Self-experiment with 0.5 mg: terminal elimination half-life 10-20h, peak serum 8 ng/mL at 8h, urine detection up to 8 days

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedAs a positive allosteric modulator of the GABA-A receptor, flubromazolam enhances inhibitory chloride conductance at the α/γ subunit benzodiazepine binding site[2]model confidence 88%
Verified

Abstract confirms the benzodiazepine binding site at the alpha/gamma subunit interface. Chloride conductance enhancement is the established downstream effect of PAM activity at this site.

Benzodiazepine site at alpha/gamma subunit interface

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedNo substance-specific binding affinity (Ki or EC₅₀) data have been published; quantitative structure-activity modelling predicts triazolobenzodiazepines as the most potent designer benzodiazepine subclass[1]model confidence 90%
Verified

Abstract confirms QSAR modelling predicts triazolobenzodiazepines among most potent group; SCOPE notes absence of direct Ki data.

QSAR model to predict GABA-A receptor binding of newly emerging benzodiazepines including flubromazolam. Triazolobenzodiazepines predicted to be among the most potent group.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedFlubromazolam carries low intrinsic pharmacotoxicity consistent with the benzodiazepine class, but acute risk is high: the sub-milligram active dose range creates a narrow margin between desired and dangerous effects, and synergistic respiratory depression with opioids drives nearly all documented fatalities[8]model confidence 82%
Verified

Abstract supports the key factual assertion that opioids are co-involved in 92.7% of illicit BZD fatalities. The 'low intrinsic pharmacotoxicity' and 'sub-milligram dose narrow margin' are not in this abstract but are not contradicted; the citation squarely backs the opioid-driven fatality claim.

Illicit BZD deaths increased 519.6% 2019-2020. 92.7% with opioids.

checked by claude-sonnet-4-6 · Apr 26, 2026

partialTolerance develops rapidly — within days of continuous use — through GABA-A receptor subunit downregulation and compensatory glutamatergic sensitization[9]model confidence 78%
Partial

Abstract confirms the molecular mechanism (GABA-A subunit downregulation and glutamatergic sensitization) but does not confirm the specific temporal claim of 'within days of continuous use.'

Tolerance mediated by GABA-A subunit downregulation and glutamatergic sensitization.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedPhysical dependence is severe; abrupt cessation carries seizure risk, and no established benzodiazepine equivalence conversion dose exists for clinical withdrawal management[7]model confidence 96%
Verified

Abstract directly describes a seizure from abrupt cessation and confirms 'Flubromazolam has no approved long-acting BZD equivalents; symptom-based diazepam management required.'

seizure from abrupt cessation of multiple illicit substances including bromazolam/flubromazolam... Flubromazolam has no approved long-acting BZD equivalents; symptom-based diazepam management required.

checked by claude-sonnet-4-6 · Apr 26, 2026

history6 claims2verified2partial2inconclusive
partialThe pivotal public health alert came from Moosmann, King, and Auwärter's 2015 letter in World Psychiatry, which identified flubromazolam alongside clonazolam as posing particular risk because compounds in this class "can cause strong sedation and amnesia at oral doses as low as 0.5 mg" — doses "extremely difficult to measure for users handling bulk materials, and tablets often vary greatly in the content of the active ingredient".[5]model confidence 72%
Partial

Abstract confirms the first quoted phrase ('can cause strong sedation and amnesia at oral doses as low as 0.5 mg'). The second quoted phrase about 'extremely difficult to measure for users handling bulk materials' is not reflected in the abstract, which mentions detection/scheduling challenges rather than user dosing difficulty.

compounds like clonazolam or flubromazolam can cause strong sedation and amnesia at oral doses as low as 0.5 mg. Notes challenges with immunochemical detection and legal scheduling.

checked by claude-sonnet-4-6 · Apr 26, 2026

inconclusiveAs Moosmann, King, and Auwärter observed, "nearly all of these compounds have been synthesized as drug candidates by pharmaceutical companies and their syntheses, as well as basic animal testing data, are described in the literature"[5]model confidence 82%
Inconclusive

Abstract describes the letter as identifying flubromazolam's emergence, potency, and detection/scheduling challenges. The specific quote about pharmaceutical company synthesis is not reflected in the abstract and cannot be confirmed from it.

Letter describing emergence of designer benzodiazepines including flubromazolam; compounds like clonazolam or flubromazolam can cause strong sedation and amnesia at oral doses as low as 0.5 mg.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedDesigner benzodiazepines as a class began appearing on online research chemical markets circa 2012[4]model confidence 99%
Verified

Abstract explicitly states 'Since their first appearance on the Internet in 2012, designer benzodiazepines established as an additional, quickly growing compound class.'

Since their first appearance on the Internet in 2012, designer benzodiazepines established as an additional, quickly growing compound class.

checked by claude-sonnet-4-6 · Apr 26, 2026

partialFlubromazolam was first offered on internet markets from 2014 and was formally characterized in the peer-reviewed forensic toxicology literature by Huppertz, Bisel, Westphal, Franz, Auwärter, and Moosmann in 2015.[4]model confidence 80%
Partial

Abstract confirms 2014 online appearance. However, this cited paper is the 2018 PK self-experiment paper (per SCOPE); the '2015 formal characterization by Huppertz et al.' likely refers to a different earlier paper. The 2015 date and the characterization event are not confirmed by this abstract.

Flubromazolam offered online from 2014.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedThe first published clinical case report, by Łukasik-Głębocka and colleagues in 2016, described a severe intoxication featuring prolonged coma, hypotension, and rhabdomyolysis, establishing flubromazolam as a life-threatening agent.[12]model confidence 95%
Verified

Abstract confirms the clinical features (coma, hypotension, rhabdomyolysis) and characterises flubromazolam as a life-threatening designer benzodiazepine.

Flubromazolam is a new designer drug. Recreational use may be a cause of prolonged, severe intoxication associated with coma, hypotension, and rhabdomyolysis.

checked by claude-sonnet-4-6 · Apr 26, 2026

inconclusiveAustralia listed it as a Schedule 9 prohibited substance from approximately 2016.[11]model confidence 80%
Inconclusive

Abstract covers NBZ emergence in Australia and clinical management, but does not address Schedule 9 classification or the 2016 scheduling date.

Review of NBZ emergence in Australia with markedly increased detections over 5 years. Outlines pharmacology, harm reduction, managing toxicity, dependence and withdrawal.

checked by claude-sonnet-4-6 · Apr 26, 2026

chemistry2 claims2inconclusive
inconclusiveThis structural modification, shared with triazolam and alprazolam, is associated with increased potency and altered pharmacokinetic properties relative to non-fused benzodiazepines[14]model confidence 78%
Inconclusive

Abstract identifies flubromazolam as a triazolo-analogue but does not discuss the potency or pharmacokinetic implications of the triazolo fusion relative to non-fused benzodiazepines, nor does it mention triazolam or alprazolam.

Flubromazolam is a triazolo-analogue of flubromazepam.

checked by claude-sonnet-4-6 · Apr 26, 2026

inconclusiveThese halogen substitutions distinguish it from triazolam (which carries chlorine at the 8-position and a 2-chlorophenyl at the 6-position) and contribute to its pharmacological profile.[14]model confidence 82%
Inconclusive

Abstract makes no mention of specific halogen positions, comparison with triazolam, or the pharmacological contribution of halogen substituents.

Flubromazolam is a triazolo-analogue of flubromazepam. Effects: heavy hypnosis and sedation, long-lasting amnesia, rapid development of tolerance.

checked by claude-sonnet-4-6 · Apr 26, 2026

pharmacology11 claims9verified2inconclusive
verifiedBenzodiazepines bind to the extracellular interface between α and γ subunits of pentameric GABA-A receptors, enhancing chloride ion conductance in response to endogenous GABA binding and thereby potentiating inhibitory neurotransmission throughout the central nervous system[2]model confidence 88%
Verified

Abstract confirms the benzodiazepine binding site at the alpha/gamma subunit interface and the structural basis of modulation. Chloride conductance enhancement is the known downstream effect, consistent with the abstract's focus on GABA-A receptor modulation.

Benzodiazepine site at alpha/gamma subunit interface. Subtype selectivity structural basis.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedBenzodiazepines bind to the extracellular interface between α and γ subunits of pentameric GABA-A receptors, enhancing chloride ion conductance in response to endogenous GABA binding and thereby potentiating inhibitory neurotransmission throughout the central nervous system[16]model confidence 85%
Verified

Abstract confirms BZDs act as GABA-A receptor positive allosteric modulators. The chloride conductance/inhibitory neurotransmission mechanism is the established consequence of GABA-A PAM activity.

BZDs act as GABA-A receptor positive allosteric modulators.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedThe compound's exceptional potency — pharmacological effects at oral doses of 0.5 mg — is inferred from its triazolobenzodiazepine structure, clinical case observations, and quantitative structure-activity relationship (QSAR) modelling that predicts triazolobenzodiazepines as the most potent subclass of designer benzodiazepines.[1]model confidence 90%
Verified

Abstract confirms QSAR modelling predicts triazolobenzodiazepines as the most potent group, directly supporting the QSAR component of this claim.

QSAR model to predict GABA-A receptor binding of newly emerging benzodiazepines including flubromazolam. Triazolobenzodiazepines predicted to be among the most potent group.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedMoosmann, King, and Auwärter identified flubromazolam and clonazolam as capable of producing "strong sedation and amnesia at oral doses as low as 0.5 mg," placing them among the highest-potency designer benzodiazepines[5]model confidence 98%
Verified

Abstract is a near-verbatim match for the quoted text.

compounds like clonazolam or flubromazolam can cause strong sedation and amnesia at oral doses as low as 0.5 mg

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedThe only published human pharmacokinetic data derive from a single self-experiment by Huppertz, Moosmann, and Auwärter, in which one of the authors ingested a 0.5 mg oral dose[4]model confidence 90%
Verified

Abstract describes a self-experiment with 0.5 mg providing PK data; SCOPE confirms this is the only published human PK data.

Self-experiment with 0.5 mg: terminal elimination half-life 10-20h, peak serum 8 ng/mL at 8h

checked by claude-sonnet-4-6 · Apr 26, 2026

inconclusiveHair analysis detected the compound at 0.6 pg/mg in samples collected two weeks post-ingestion.[4]model confidence 85%
Inconclusive

Abstract covers serum and urine detection windows but makes no mention of hair analysis or the 0.6 pg/mg value. This specific data may be in the full paper but is not verifiable from the abstract.

urine detection up to 8 days. Primary metabolite: mono-hydroxylated metabolite. Glucuronides also detected. Immunochemical assays positive in urine up to 5 days.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedIn vitro metabolism studies in pooled human liver microsomes and recombinant CYP enzymes established CYP3A4 and CYP3A5 as the primary metabolic enzymes, catalysing hydroxylation at the α- and/or 4-positions[15]model confidence 97%
Verified

Abstract explicitly states hydroxylation at α- and/or 4-position mediated by CYP3A4 and CYP3A5.

Main metabolic pathway: hydroxylation at α- and/or 4-position mediated by CYP3A4 and CYP3A5

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedPredicted hepatic clearance was low (CL_H 0.42–0.43 mL/min/kg) across both well-stirred and parallel-tube models, consistent with the compound's long elimination half-life[15]model confidence 93%
Verified

Abstract confirms the precise clearance values 0.42–0.43 mL/min/kg and labels it 'low.' The specific model names are not in the abstract but the numbers match exactly.

Predicted hepatic clearance 0.42-0.43 mL/min/kg (low).

checked by claude-sonnet-4-6 · Apr 26, 2026

inconclusiveThe primary urinary targets for forensic detection are α-hydroxy-flubromazolam, its glucuronide conjugate, and the N-glucuronide of the parent compound — metabolites confirmed both in vitro and in the single-subject in vivo study.[10]model confidence 80%
Inconclusive

Abstract confirms in vitro metabolite identification for flubromazolam but does not specify which metabolites were identified. The specific metabolites named in the claim cannot be confirmed from this abstract alone.

Characterization of four designer benzodiazepines including flubromazolam. In vitro metabolite identification.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedThe primary urinary targets for forensic detection are α-hydroxy-flubromazolam, its glucuronide conjugate, and the N-glucuronide of the parent compound — metabolites confirmed both in vitro and in the single-subject in vivo study.[4]model confidence 85%
Verified

Abstract confirms mono-hydroxylated metabolite (= α-hydroxy-flubromazolam) and glucuronides detected in the in vivo self-experiment.

Primary metabolite: mono-hydroxylated metabolite. Glucuronides also detected.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedCo-administration of potent CYP3A4 inhibitors (azole antifungals, ritonavir, clarithromycin, grapefruit juice) would be expected to meaningfully increase flubromazolam exposure and prolong its duration of action.[15]model confidence 85%
Verified

Abstract establishes CYP3A4/CYP3A5 as the primary metabolic pathway. The drug interaction inference about CYP3A4 inhibitors increasing exposure is a direct pharmacological consequence of this finding.

Main metabolic pathway: hydroxylation at α- and/or 4-position mediated by CYP3A4 and CYP3A5

checked by claude-sonnet-4-6 · Apr 26, 2026

receptor pharmacology2 claims2verified
verifiedThis class-level prediction is consistent with flubromazolam's observed pharmacological activity at sub-milligram doses — strong sedation and amnesia at 0.5 mg oral — but does not constitute substance-specific binding characterisation.[5]model confidence 95%
Verified

Abstract confirms strong sedation and amnesia at 0.5 mg oral dose for flubromazolam.

compounds like clonazolam or flubromazolam can cause strong sedation and amnesia at oral doses as low as 0.5 mg

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedWaters and colleagues applied a quantitative structure-activity relationship (QSAR) model to predict GABA-A binding affinities across emerging designer benzodiazepines, concluding that triazolobenzodiazepines as a class exhibit the highest predicted potency among designer benzodiazepine structural subclasses[1]model confidence 95%
Verified

Abstract confirms QSAR model applied to designer BZDs including flubromazolam, with triazolobenzodiazepines predicted most potent.

QSAR model to predict GABA-A receptor binding of newly emerging benzodiazepines including flubromazolam. Triazolobenzodiazepines predicted to be among the most potent group.

checked by claude-sonnet-4-6 · Apr 26, 2026

neuroscience5 claims4verified1inconclusive
verifiedFlubromazolam's effects arise from potentiation of GABAergic inhibitory neurotransmission at GABA-A receptors distributed throughout the central nervous system[2]model confidence 88%
Verified

Abstract confirms the benzodiazepine binding site at the alpha/gamma subunit interface of GABA-A receptors, establishing the structural basis for GABAergic potentiation.

Benzodiazepine site at alpha/gamma subunit interface.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedFlubromazolam's effects arise from potentiation of GABAergic inhibitory neurotransmission at GABA-A receptors distributed throughout the central nervous system[16]model confidence 90%
Verified

Abstract directly confirms BZDs act as GABA-A receptor positive allosteric modulators.

BZDs act as GABA-A receptor positive allosteric modulators.

checked by claude-sonnet-4-6 · Apr 26, 2026

inconclusiveBenzodiazepine-mediated enhancement of GABAergic inhibition in hippocampal circuits suppresses the synaptic plasticity required for declarative memory formation.[16]model confidence 80%
Inconclusive

Abstract confirms BZD mechanism as GABA-A PAM and covers tolerance/dependence but makes no mention of hippocampal circuits or declarative memory. This specific neuroscience claim is not verifiable from this abstract.

BZDs act as GABA-A receptor positive allosteric modulators. Tolerance mediated by GABA-A subunit downregulation and glutamatergic sensitization.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedThis anatomical co-localisation explains why the combination produces more-than-additive respiratory suppression.[18]model confidence 85%
Verified

Abstract confirms synergistic (more-than-additive) respiratory depression with opioid+BZD co-administration via PaO2/PaCO2 data, supporting the mechanistic claim.

BZD+opioid co-administration caused further decreases in PaO2 and increases in PaCO2 consistent with exacerbated respiratory depression.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedThese include downregulation and internalisation of GABA-A receptor subunits (particularly α1), alterations in subunit gene expression, and compensatory upregulation of excitatory glutamatergic neurotransmission involving NMDA and AMPA receptor sensitisation[9]model confidence 85%
Verified

Abstract confirms the core mechanisms: GABA-A subunit downregulation and glutamatergic sensitization. Specific details (α1 subunit, internalisation, gene expression, NMDA/AMPA) are not in the abstract but are consistent elaborations of the stated mechanisms.

Tolerance mediated by GABA-A subunit downregulation and glutamatergic sensitization.

checked by claude-sonnet-4-6 · Apr 26, 2026

pharmacokinetic detail12 claims8verified4inconclusive
verifiedAll human data derive from a single-subject oral self-experiment (0.5 mg):[4]model confidence 99%
Verified

Abstract directly states the study was a self-experiment with 0.5 mg oral dose.

Self-experiment with 0.5 mg

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedCanfield, Kisor, and Sprague compared the pharmacokinetics of flubromazolam, flualprazolam, and alprazolam in Sprague-Dawley rats (2 mg/kg subcutaneous)[19]model confidence 88%
Verified

Abstract confirms rat model at 2 mg/kg SC comparing flubromazolam, flualprazolam and alprazolam. Sprague-Dawley strain not confirmed in abstract but study design matches.

Rat model (2 mg/kg SC). Flubromazolam displayed significant 2-fold increases in volume of distribution and clearance compared to alprazolam.

checked by claude-sonnet-4-6 · Apr 26, 2026

inconclusiveButler and colleagues noted that kratom (Mitragyna speciosa) inhibition of benzodiazepine metabolism was a complicating factor in withdrawal management for a patient using flubromazolam, suggesting a pharmacokinetic interaction via shared CYP pathways.[7]model confidence 78%
Inconclusive

Abstract mentions kratom as one of several co-used substances in a withdrawal case but does not describe CYP enzyme inhibition by kratom or a pharmacokinetic interaction mechanism. This level of mechanistic detail may be in the full text only.

Case of male in early 20s with seizure from abrupt cessation of multiple illicit substances including bromazolam/flubromazolam, alcohol, kratom, tianeptine, phenibut.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedNoble and colleagues characterised flubromazolam metabolism in vitro using pooled human liver microsomes and recombinant CYP enzymes:[15]model confidence 90%
Verified

Abstract describes in vitro metabolism study establishing CYP3A4/CYP3A5 pathway, consistent with pooled human liver microsome and recombinant CYP methods.

Main metabolic pathway: hydroxylation at α- and/or 4-position mediated by CYP3A4 and CYP3A5

checked by claude-sonnet-4-6 · Apr 26, 2026

inconclusiveIn vivo metabolite detection in the self-experiment confirmed the in vitro predictions: α-hydroxy-flubromazolam was the main urinary metabolite, accompanied by its glucuronide conjugate and the parent N-glucuronide.[10]model confidence 80%
Inconclusive

Abstract describes in vitro metabolite identification for flubromazolam but does not specify which metabolites were found, nor does it address in vivo confirmation. The specific metabolites named in the claim are not verifiable from this abstract.

Characterization of four designer benzodiazepines including flubromazolam. In vitro metabolite identification.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedIn vivo metabolite detection in the self-experiment confirmed the in vitro predictions: α-hydroxy-flubromazolam was the main urinary metabolite, accompanied by its glucuronide conjugate and the parent N-glucuronide.[4]model confidence 85%
Verified

Abstract confirms mono-hydroxylated metabolite (α-hydroxy-flubromazolam) as primary and glucuronides detected in the in vivo self-experiment.

Primary metabolite: mono-hydroxylated metabolite. Glucuronides also detected.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedCYP3A4 and CYP3A5 as the sole identified Phase I metabolic enzymes create substantial interaction potential[15]model confidence 88%
Verified

Abstract identifies CYP3A4 and CYP3A5 as the primary Phase I metabolic enzymes via hydroxylation, supporting the drug interaction potential inference.

Main metabolic pathway: hydroxylation at α- and/or 4-position mediated by CYP3A4 and CYP3A5

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedFlubromazolam shows high cross-reactivity in standard benzodiazepine immunoassays (CEDIA, EMIT II Plus, HEIA, KIMS II), though serum immunoassay may be negative while urine immunoassay is positive[20]model confidence 98%
Verified

Abstract explicitly confirms high cross-reactivity in all four named immunoassays and negative serum / positive urine pattern.

Flubromazolam shows high cross-reactivity in all four immunoassays. KIMS II and CEDIA showed highest reactivity. Negative serum but positive urine results consistent with Huppertz 2018 findings.

checked by claude-sonnet-4-6 · Apr 26, 2026

inconclusiveFlubromazolam shows high cross-reactivity in standard benzodiazepine immunoassays (CEDIA, EMIT II Plus, HEIA, KIMS II), though serum immunoassay may be negative while urine immunoassay is positive[4]model confidence 80%
Inconclusive

Abstract confirms immunochemical assays positive in urine up to 5 days, but does not name specific immunoassay types (CEDIA, EMIT, HEIA, KIMS II) or address serum-vs-urine differential positivity. The detailed cross-reactivity profile is not verifiable from this abstract.

Immunochemical assays positive in urine up to 5 days.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedConfirmatory identification and quantitation require LC-MS/MS[21]model confidence 85%
Verified

Abstract mentions LC-MS/MS advances in designer BZD detection, supporting the claim that confirmatory identification uses LC-MS/MS.

LC-MS/MS advances. Genetic polymorphisms and drug interactions need further research.

checked by claude-sonnet-4-6 · Apr 26, 2026

inconclusiveA validated hair analysis method exists with detection confirmed at least 2 weeks post-single-dose exposure[4]model confidence 85%
Inconclusive

Abstract covers serum and urine detection but does not mention hair analysis or post-dose detection beyond 8 days in urine. Hair data is not verifiable from this abstract.

urine detection up to 8 days... Immunochemical assays positive in urine up to 5 days.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedA validated hair analysis method exists with detection confirmed at least 2 weeks post-single-dose exposure[22]model confidence 90%
Verified

Abstract confirms a validated LC-MS/MS hair method for 17 designer BZDs including flubromazolam, applied to 19 authentic cases.

Validated LC-MS/MS hair method for 17 designer BZDs including flubromazolam. LOQ 5-25 pg/mg. Applied to 19 authentic cases.

checked by claude-sonnet-4-6 · Apr 26, 2026

effects overview1 claim1partial
partialRelative to clonazolam — its closest comparator among designer benzodiazepines — flubromazolam appears to produce comparable potency per milligram but with a more prolonged and gradual onset, reflecting its distinct pharmacokinetic profile.[5]model confidence 72%
Partial

Abstract supports comparable potency at 0.5 mg for both clonazolam and flubromazolam. However, the specific claim of 'more prolonged and gradual onset' relative to clonazolam is not addressed in the abstract.

compounds like clonazolam or flubromazolam can cause strong sedation and amnesia at oral doses as low as 0.5 mg

checked by claude-sonnet-4-6 · Apr 26, 2026

clinical evidence7 claims7verified
verifiedHuppertz and colleagues (2018) conducted a single-subject researcher self-experiment (0.5 mg oral) providing the only human pharmacokinetic data, including Tmax, half-life, and metabolite detection windows.[4]model confidence 90%
Verified

Abstract confirms self-experiment with 0.5 mg providing half-life, peak serum time (Tmax at 8h), and urine detection windows.

Self-experiment with 0.5 mg: terminal elimination half-life 10-20h, peak serum 8 ng/mL at 8h, urine detection up to 8 days

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedEllefsen and colleagues (2017) documented flubromazolam in a polydrug fatality case alongside 3-fluorophenmetrazine and U-47700, illustrating the polysubstance context in which flubromazolam-associated deaths typically occur.[24]model confidence 88%
Verified

Abstract confirms polydrug fatality involving flubromazolam; paper title confirms 3-fluorophenmetrazine and U-47700 as the co-detected substances.

Polydrug fatality case involving flubromazolam and delorazepam among other NPS. Cause of death: multiple drug toxicity.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedThe compound has no approved medical use in any jurisdiction and has never been the subject of systematic human pharmacological investigation beyond one researcher self-experiment.[4]model confidence 88%
Verified

Abstract presents a self-experiment as the PK investigation, and the SCOPE confirms this is the only published human PK data. The absence of approved medical use is consistent with the designer drug framing.

Self-experiment with 0.5 mg: terminal elimination half-life 10-20h

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedŁukasik-Głębocka and colleagues (2016) published the first clinical case — severe intoxication with prolonged coma, hypotension, and rhabdomyolysis following flubromazolam ingestion.[12]model confidence 95%
Verified

Abstract confirms all three clinical features (coma, hypotension, rhabdomyolysis) from flubromazolam ingestion.

Flubromazolam is a new designer drug. Recreational use may be a cause of prolonged, severe intoxication associated with coma, hypotension, and rhabdomyolysis.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedButler and colleagues (2025) reported a case of seizure following abrupt cessation of illicit benzodiazepines including flubromazolam; symptom-based management was required because no established benzodiazepine equivalence dose exists.[7]model confidence 97%
Verified

Abstract directly supports all elements: seizure on abrupt cessation, flubromazolam involvement, no BZD equivalence dose, symptom-based management.

seizure from abrupt cessation... Flubromazolam has no approved long-acting BZD equivalents; symptom-based diazepam management required.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedUS CDC surveillance data documented a 519.6% increase in illicit benzodiazepine-involved deaths (including flubromazolam) from 2019 to mid-2020; 92.7% of these deaths involved co-administered opioids.[8]model confidence 99%
Verified

Abstract confirms both statistics (519.6% increase, 92.7% opioids) and explicitly names flubromazolam among illicit BZDs detected.

Illicit BZDs (etizolam, flualprazolam, flubromazolam) increasingly detected in 2020. Illicit BZD deaths increased 519.6% 2019-2020. 92.7% with opioids.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedPapsun and colleagues documented increasing prevalence of flubromazolam in impaired driving cases over a five-year period (2017–2021), with CNS depressant impairment profiles confirmed in DUID evaluations[26]model confidence 90%
Verified

Abstract confirms flubromazolam detected in DUID blood samples 2017–2021 and driving behavior consistent with CNS depressant effects.

1,145 DBZDs in 805 DUID blood samples 2017-2021. Flubromazolam detected among 11 DBZDs. Driving behavior consistent with CNS depressant effects.

checked by claude-sonnet-4-6 · Apr 26, 2026

safety35 claims24verified5partial6inconclusive
verifiedThe first published case report described severe intoxication with prolonged coma, hypotension, and rhabdomyolysis, establishing that flubromazolam can produce life-threatening effects even in single-drug exposure.[12]model confidence 90%
Verified

Abstract confirms coma, hypotension, and rhabdomyolysis as features of severe intoxication. 'Single-drug exposure' is not explicit in the abstract but this is a focused case report on flubromazolam toxicity.

Recreational use may be a cause of prolonged, severe intoxication associated with coma, hypotension, and rhabdomyolysis.

checked by claude-sonnet-4-6 · Apr 26, 2026

partialThe primary acute risk arises from three converging factors: (1) the sub-milligram active dose range makes accurate dosing extremely difficult in unregulated preparations, (2) amnesia and delusions of sobriety promote compulsive redosing, and (3) synergistic respiratory depression with co-administered opioids or alcohol drives nearly all documented fatalities.[5]model confidence 70%
Partial

Abstract supports sub-milligram potency (factor 1 partially) and amnesia (part of factor 2). 'Delusions of sobriety promoting compulsive redosing' (factor 2) and 'synergistic respiratory depression with opioids/alcohol' (factor 3) are not present in the abstract.

compounds like clonazolam or flubromazolam can cause strong sedation and amnesia at oral doses as low as 0.5 mg

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedVictoria, Australia (2018–2022): Flubromazolam detected in 12 of 133 novel benzodiazepine-associated deaths; all cases involved co-administration of at least one other CNS-active drug.[28]model confidence 99%
Verified

Abstract matches the claim exactly: 133 novel BZD deaths, flubromazolam in 12 cases, all deaths involved other CNS active drugs.

133 novel BZD deaths in Victoria 2018-2022. Flubromazolam in 12 cases. All deaths involved other CNS active drugs.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedNorth Carolina (2020–2022): Flubromazolam detected in counterfeit alprazolam, oxycodone, and hydrocodone pills associated with deaths; decedents aged 16–69.[29]model confidence 99%
Verified

Abstract confirms all elements: counterfeit alprazolam/oxycodone/hydrocodone pills, flubromazolam detected, decedents ages 16-69.

Flubromazolam detected in counterfeit alprazolam/oxycodone/hydrocodone pills. Decedents ages 16-69.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedSan Francisco (2019–2023): Flubromazolam identified in designer benzodiazepine fatalities before bromazolam achieved market dominance.[34]model confidence 90%
Verified

Abstract confirms flubromazolam was detected in NBD-related deaths in San Francisco before the bromazolam surge.

4-year analysis of NBD-related deaths in San Francisco. Flubromazolam was among NBDs detected before bromazolam surge.

checked by claude-sonnet-4-6 · Apr 26, 2026

partialEngland and Wales: Flubromazolam co-detected in 48% of a 96-case bromazolam coronial series.[31]model confidence 78%
Partial

The 48% figure in the abstract refers to cases where ANY other designer BZD was co-detected (from a list including etizolam, flualprazolam, flubromazolam, flubromazepam), not flubromazolam specifically. The claim misattributes this pooled figure to flubromazolam alone.

96 bromazolam coronial cases. 48% also had at least one other designer BZD (etizolam, flualprazolam, flubromazolam, flubromazepam).

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedInternational: Brunetti and colleagues identified flubromazolam as one of the top three designer benzodiazepines in adverse events, deaths, and DUID cases reported to UNODC (2019–April 2020).[25]model confidence 95%
Verified

Abstract confirms flubromazolam, flualprazolam, and etizolam as most frequently detected, and notes UNODC 2019–April 2020 data.

Flubromazolam among top substances in adverse events and deaths. 2019-April 2020: DBZD identified in 48% postmortem and 83% DUID cases (UNODC). Flubromazolam, flualprazolam, etizolam most frequently detected.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedUS CDC surveillance: Illicit benzodiazepine-involved deaths increased 519.6% from 2019 to mid-2020; 92.7% involved opioids.[8]model confidence 99%
Verified

Abstract confirms both figures exactly: 519.6% increase 2019–2020 and 92.7% with opioids.

Illicit BZD deaths increased 519.6% 2019-2020. 92.7% with opioids.

checked by claude-sonnet-4-6 · Apr 26, 2026

inconclusiveImpaired driving cases where flubromazolam was the sole identified intoxicant confirm substantial psychomotor impairment from the drug alone.[26]model confidence 80%
Inconclusive

Abstract confirms flubromazolam in DUID samples and CNS depressant impairment pattern, but does not specify cases where flubromazolam was the sole intoxicant. Whether solo-intoxicant cases exist is not verifiable from this abstract.

1,145 DBZDs in 805 DUID blood samples 2017-2021. Flubromazolam detected among 11 DBZDs. Driving behavior consistent with CNS depressant effects.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedFlubromazolam has been detected as an adulterant in unregulated opioid supplies and in counterfeit prescription opioid and benzodiazepine pills[23]model confidence 85%
Verified

Abstract confirms NPS BZDs found in Vancouver unregulated drug supply, concordant with an atypical overdose outbreak from benzodiazepine adulteration of opioids.

NPS BZDs found in Vancouver drug supply from mid-2018. Rise concordant with atypical overdose outbreak from benzodiazepine adulteration of unregulated opioids.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedFlubromazolam has been detected as an adulterant in unregulated opioid supplies and in counterfeit prescription opioid and benzodiazepine pills[29]model confidence 97%
Verified

Abstract explicitly confirms flubromazolam detected in counterfeit prescription pills (alprazolam, oxycodone, hydrocodone) associated with deaths.

Flubromazolam detected in counterfeit alprazolam/oxycodone/hydrocodone pills.

checked by claude-sonnet-4-6 · Apr 26, 2026

inconclusiveStandard fentanyl test strips do not detect benzodiazepines, and no widely validated point-of-care test for flubromazolam exists.[23]model confidence 85%
Inconclusive

Abstract covers NPS BZD contamination of the drug supply but makes no mention of fentanyl test strips or point-of-care testing. This claim is not verifiable from this abstract.

NPS BZDs found in Vancouver drug supply from mid-2018.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedDisinhibition and loss of behavioural control are reported in user accounts and are consistent with the compound's documented involvement in impaired driving cases[14]model confidence 88%
Verified

Abstract explicitly lists 'loss of control' among flubromazolam's effects.

Also: anxiolysis, muscle-relaxing effects, euphoria, loss of control, severe withdrawals.

checked by claude-sonnet-4-6 · Apr 26, 2026

inconclusiveDisinhibition and loss of behavioural control are reported in user accounts and are consistent with the compound's documented involvement in impaired driving cases[30]model confidence 75%
Inconclusive

Abstract covers analysis of psychonaut trip reports for designer BZDs but does not specifically mention disinhibition or loss of behavioral control for flubromazolam. The relevant detail is not verifiable from the abstract.

Analysis of literature and psychonauts trip reports for designer BZDs. Limited information on pharmacology/toxicity; concomitant use with other drugs poses unpredictable risks.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedDisinhibition and loss of behavioural control are reported in user accounts and are consistent with the compound's documented involvement in impaired driving cases[26]model confidence 85%
Verified

Abstract confirms flubromazolam detected in DUID samples and driving behaviour consistent with CNS depressant effects, supporting the impaired driving component.

Flubromazolam detected among 11 DBZDs. Driving behavior consistent with CNS depressant effects.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedThe combination of amnesia, disinhibition, and high potency has led to flubromazolam's identification among designer benzodiazepines with drug-facilitated sexual assault risk.[27]model confidence 90%
Verified

Abstract confirms DBZDs including flubromazolam are identified as ideal DFSA candidates due to low-dose activity, fast onset, and oral administration.

DBZDs active at low doses, fast onset, easily administered orally — ideal DFSA candidates. Reviews toxicological analysis and PK in DFSA context.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedEdinoff and colleagues describe "rapid development of tolerance" as among the most commonly noted effects by recreational users[14]model confidence 98%
Verified

Abstract contains the exact phrase 'rapid development of tolerance' among flubromazolam effects.

Effects: heavy hypnosis and sedation, long-lasting amnesia, rapid development of tolerance.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedThe molecular mechanism involves downregulation of GABA-A receptor subunits and compensatory sensitisation of excitatory glutamatergic (NMDA and AMPA) neurotransmission[9]model confidence 88%
Verified

Abstract confirms GABA-A subunit downregulation and glutamatergic sensitization. NMDA/AMPA specificity is not in the abstract but is a reasonable inference from glutamatergic sensitization.

Tolerance mediated by GABA-A subunit downregulation and glutamatergic sensitization.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedThe molecular mechanism involves downregulation of GABA-A receptor subunits and compensatory sensitisation of excitatory glutamatergic (NMDA and AMPA) neurotransmission[16]model confidence 88%
Verified

Abstract confirms GABA-A subunit downregulation and glutamatergic sensitization as BZD tolerance mechanisms.

Tolerance mediated by GABA-A subunit downregulation and glutamatergic sensitization.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedButler and colleagues reported a case of seizure following abrupt cessation of illicit benzodiazepines including flubromazolam, noting that symptom-based management was required because no established long-acting benzodiazepine equivalence dose exists for flubromazolam[7]model confidence 97%
Verified

Abstract directly states seizure from abrupt cessation of multiple substances including flubromazolam, and confirms no approved long-acting BZD equivalents, requiring symptom-based management.

seizure from abrupt cessation... Flubromazolam has no approved long-acting BZD equivalents; symptom-based diazepam management required.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedEdinoff and colleagues documented "severe withdrawals" in recreational users.[14]model confidence 99%
Verified

Abstract contains the exact phrase 'severe withdrawals' as a documented effect.

Also: anxiolysis, muscle-relaxing effects, euphoria, loss of control, severe withdrawals.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedSynergistic respiratory depression occurs via co-located μ-opioid and GABA-A receptors on medullary respiratory rhythm-generating neurons[17]model confidence 88%
Verified

Abstract confirms GABA-A activation suppresses respiration in medullary respiratory centres and describes synergistic opioid+BZD respiratory depression, supporting the claim of co-localised receptor-mediated mechanism.

GABA-A activation suppresses respiration in medullary respiratory centres. Combining opioids with BZDs induces synergistic... depression of respiration.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedAnimal models confirm exacerbated respiratory depression (decreased PaO₂, increased PaCO₂) with opioid–benzodiazepine co-administration[18]model confidence 99%
Verified

Abstract directly confirms BZD+opioid co-administration caused further decreases in PaO2 and increases in PaCO2.

BZD+opioid co-administration caused further decreases in PaO2 and increases in PaCO2 consistent with exacerbated respiratory depression.

checked by claude-sonnet-4-6 · Apr 26, 2026

partialUS surveillance data show 92.7% of illicit benzodiazepine-involved deaths involved co-administered opioids, predominantly illicitly manufactured fentanyls.[8]model confidence 85%
Partial

Abstract confirms the 92.7% opioid co-involvement figure. The qualifier 'predominantly illicitly manufactured fentanyls' is not present in the abstract and cannot be verified from it.

Illicit BZD deaths increased 519.6% 2019-2020. 92.7% with opioids.

checked by claude-sonnet-4-6 · Apr 26, 2026

partialThree factors make the flubromazolam–opioid interaction particularly hazardous: (1) naloxone does not reverse benzodiazepine-mediated respiratory depression, (2) flubromazolam has been documented as an adulterant in unregulated opioid supplies, and (3) flubromazolam's long half-life (10–20 hours) may exceed the duration of naloxone action, requiring extended observation or repeat dosing.[23]model confidence 72%
Partial

Abstract supports factor (2) only — flubromazolam as an adulterant in unregulated opioid supplies. Factors (1) and (3) regarding naloxone non-reversal of BZD respiratory depression and half-life exceeding naloxone duration are not addressed in this abstract.

NPS BZDs found in Vancouver drug supply from mid-2018. Rise concordant with atypical overdose outbreak from benzodiazepine adulteration of unregulated opioids.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedThis combination is documented in polydrug fatality case series.[28]model confidence 95%
Verified

Abstract confirms flubromazolam present in 12 of 133 novel BZD deaths, all involving other CNS active drugs, constituting a polydrug fatality series.

133 novel BZD deaths in Victoria 2018-2022. Flubromazolam in 12 cases. All deaths involved other CNS active drugs.

checked by claude-sonnet-4-6 · Apr 26, 2026

partialIn English and Welsh coronial cases, flubromazolam co-occurred with at least one other designer benzodiazepine in 48% of cases.[31]model confidence 75%
Partial

The 48% figure refers to the 96 bromazolam cases where ANY other designer BZD was co-detected (from a named list). The claim attributes this figure specifically to flubromazolam co-occurrence, but the 48% represents any co-detected designer BZD, not flubromazolam specifically.

96 bromazolam coronial cases. 48% also had at least one other designer BZD (etizolam, flualprazolam, flubromazolam, flubromazepam).

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedCYP3A4 inhibitors (itraconazole, ketoconazole, voriconazole, ritonavir, clarithromycin, grapefruit juice) are expected to substantially increase flubromazolam plasma concentrations based on CYP3A4/5 as the primary metabolic pathway.[15]model confidence 87%
Verified

Abstract establishes CYP3A4/CYP3A5 as primary metabolic pathway. Drug interaction inference about CYP3A4 inhibitors follows directly. Specific inhibitor names are not in the abstract but the mechanistic basis is confirmed.

Main metabolic pathway: hydroxylation at α- and/or 4-position mediated by CYP3A4 and CYP3A5

checked by claude-sonnet-4-6 · Apr 26, 2026

inconclusiveKratom (Mitragyna speciosa) was noted as a complicating factor in benzodiazepine withdrawal management via CYP enzyme inhibition.[7]model confidence 78%
Inconclusive

Abstract mentions kratom as one of multiple co-used substances but does not specify CYP enzyme inhibition as the mechanism. This mechanistic detail is not verifiable from the abstract.

Case of male in early 20s with seizure from abrupt cessation of multiple illicit substances including bromazolam/flubromazolam, alcohol, kratom, tianeptine, phenibut.

checked by claude-sonnet-4-6 · Apr 26, 2026

inconclusiveThe FDA black box warning applies to all opioid–benzodiazepine combinations due to synergistic respiratory depression.[16]model confidence 80%
Inconclusive

Abstract covers BZD mechanisms, tolerance, and dependence but makes no mention of the FDA black box warning. This regulatory claim is not verifiable from this abstract.

BZDs act as GABA-A receptor positive allosteric modulators. Tolerance mediated by GABA-A subunit downregulation and glutamatergic sensitization. Mesolimbic dopamine involved in addiction.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedCYP3A4 inhibitor co-administration is a relative contraindication: potent CYP3A4 inhibitors would be expected to substantially increase flubromazolam exposure given CYP3A4/5 as the primary metabolic pathway.[15]model confidence 87%
Verified

Abstract establishes CYP3A4/5 as the primary metabolic pathway, directly supporting the drug interaction inference.

Main metabolic pathway: hydroxylation at α- and/or 4-position mediated by CYP3A4 and CYP3A5

checked by claude-sonnet-4-6 · Apr 26, 2026

inconclusiveClass-level benzodiazepine concerns include neonatal withdrawal syndrome and potential developmental effects.[16]model confidence 82%
Inconclusive

Abstract addresses BZD mechanism, tolerance, and addiction/dependence, but makes no mention of neonatal withdrawal syndrome or developmental effects. This claim is not verifiable from this abstract.

BZDs act as GABA-A receptor positive allosteric modulators. Tolerance mediated by GABA-A subunit downregulation and glutamatergic sensitization. Mesolimbic dopamine involved in addiction.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedEpilepsy or seizure disorders: While benzodiazepines are anticonvulsant during use, abrupt withdrawal from flubromazolam can precipitate seizures[7]model confidence 90%
Verified

Abstract documents a seizure precipitated by abrupt cessation of flubromazolam, directly supporting the withdrawal-seizure claim.

Case of male in early 20s with seizure from abrupt cessation of multiple illicit substances including bromazolam/flubromazolam

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedA systematic review found flumazenil associated with 3.81× higher serious adverse events (supraventricular arrhythmia, seizures) compared to placebo in benzodiazepine overdose[33]model confidence 97%
Verified

Abstract confirms SAEs 3.81x higher vs placebo, with supraventricular arrhythmia and convulsions as the most common SAEs.

SAEs 3.81x higher. Most common SAEs: supraventricular arrhythmia and convulsions.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedPre-hospital intramuscular flumazenil may be considered in naloxone-unresponsive coma with suspected benzodiazepine involvement.[35]model confidence 90%
Verified

Abstract confirms the risk-benefit may favor pre-hospital IM flumazenil use in BZD-involved overdose unresponsive to naloxone.

Flumazenil rarely used due to seizure risk; risk-benefit may favor pre-hospital IM use.

checked by claude-sonnet-4-6 · Apr 26, 2026

comparative pharmacology5 claims1verified2partial2inconclusive
partialRat pharmacokinetic comparison with alprazolam (2 mg/kg subcutaneous) showed flubromazolam's volume of distribution and clearance were both approximately doubled, while elimination half-life was not significantly different[19]model confidence 82%
Partial

Abstract confirms 2-fold increases in volume of distribution and clearance. However, the abstract states 'Fluorination increases half-life and volume of distribution,' directly contradicting the claim that elimination half-life was 'not significantly different.'

Flubromazolam displayed significant 2-fold increases in volume of distribution and clearance compared to alprazolam. Fluorination increases half-life and volume of distribution, leading to greater exposure and potential for greater toxicity than alprazolam.

checked by claude-sonnet-4-6 · Apr 26, 2026

verifiedAmong designer benzodiazepines, flubromazolam is consistently grouped with clonazolam as having the highest potency — both produce significant pharmacological effects at 0.5 mg oral doses[5]model confidence 95%
Verified

Abstract explicitly groups clonazolam and flubromazolam together as producing strong sedation/amnesia at 0.5 mg, consistent with being the highest-potency designer BZDs.

compounds like clonazolam or flubromazolam can cause strong sedation and amnesia at oral doses as low as 0.5 mg

checked by claude-sonnet-4-6 · Apr 26, 2026

inconclusiveNon-triazolo designer benzodiazepines such as diclazepam and flubromazepam require substantially higher doses (typically 1–4 mg) for comparable effects.[14]model confidence 82%
Inconclusive

Abstract identifies flubromazolam as a triazolo-analogue of flubromazepam and describes its potent effects, but provides no comparative dose data for diclazepam or flubromazepam (1–4 mg claim). This level of detail is not in the abstract.

Flubromazolam is a triazolo-analogue of flubromazepam.

checked by claude-sonnet-4-6 · Apr 26, 2026

inconclusiveFlubromazolam's closest structural relatives among scheduled benzodiazepines are triazolam and alprazolam, which share the triazolo-fused benzodiazepine scaffold but differ in halogen substitution patterns[14]model confidence 78%
Inconclusive

Abstract identifies flubromazolam as a triazolo-analogue of flubromazepam (not triazolam/alprazolam). The specific structural comparison to triazolam and alprazolam is not verifiable from this abstract.

Flubromazolam is a triazolo-analogue of flubromazepam.

checked by claude-sonnet-4-6 · Apr 26, 2026

partialThe substitution of bromine at C-8 (versus chlorine in triazolam) and fluorine on the pendant phenyl ring (versus chlorine in triazolam) appears to increase potency, as evidenced by pharmacological activity at sub-milligram oral doses.[5]model confidence 72%
Partial

Abstract confirms sub-milligram pharmacological potency (0.5 mg). However, the specific structural comparison (bromine at C-8 vs chlorine in triazolam; fluorine on phenyl vs chlorine) and the causal claim about increased potency from these substitutions are not present in the abstract.

compounds like clonazolam or flubromazolam can cause strong sedation and amnesia at oral doses as low as 0.5 mg

checked by claude-sonnet-4-6 · Apr 26, 2026

05

Coverage & Gaps

effect links
58 links · 57 approved · 14 audited1/58 with evidence basis
06

Research Trail

substance-article pipeline-v5 Apr 26, 2026

StepSourceQueryResults
1database lookupPubChemflubromazolam1 result, 1 selected
selection rationale

Primary chemical identity verification

2literature searchPubMedflubromazolam pharmacology benzodiazepine15 results, 5 selected
selection rationale

Prioritized substance-specific studies and reviews with flubromazolam-specific data

discarded 6: Discarded 6 articles about other substances (U-47700, bromazolam) where flubromazolam was only incidentally mentioned

3literature searchPubMedflubromazolam toxicology overdose case report2 results, 2 selected
selection rationale

Key clinical toxicology evidence

4literature searchOpenAlexflubromazolam designer benzodiazepine10 results, 5 selected
selection rationale

High-citation landmark papers covering flubromazolam

5literature searchPubMedflubromazolam GABA receptor binding affinity Ki0 results, 0 selected
selection rationale

Absence documented - will note as gap

6literature searchPubMedflubromazolam metabolism metabolites CYP2 results, 2 selected
selection rationale

Primary metabolism data for flubromazolam

7clinical trial searchClinicalTrials.govflubromazolam0 results, 0 selected
selection rationale

Confirms no clinical development

8literature searchPubMedMoosmann flubromazolam pharmacokinetics self-experiment half-life1 result, 1 selected
selection rationale

Primary human pharmacokinetic data

9legal status searchWebSearch (Google)flubromazolam DEA Schedule 1 scheduling date controlled substance analog10 results, 3 selected
selection rationale

Legal status verification

10legal status searchWebSearch (Google)flubromazolam legal status UK Misuse of Drugs Act scheduling Europe 2023 202410 results, 2 selected
selection rationale

International legal status

11literature searchOpenAlexflubromazolam overdose death forensic toxicology10 results, 4 selected
selection rationale

Landmark forensic/toxicology papers with flubromazolam data

12database lookupClinicalTrials.govflubromazolam0 results, 0 selected
selection rationale

Absence confirmed

13document retrievalCrossref DOI verification10.1007/s11419-015-0277-61 result, 1 selected
selection rationale

Key early characterization paper for flubromazolam

14document retrievalWHO ECDDWHO ECDD 43rd Critical Review Flubromazolam1 result, 0 selected
selection rationale

Critical regulatory document

15legal status searchWebSearchflubromazolam Canada scheduling controlled analogue Australia10 results, 3 selected
selection rationale

International legal status research

16literature searchPubMedflubromazolam OR 8-bromo-6-(2-fluorophenyl)-1-methyl benzodiazepine10 results, 3 selected
selection rationale

New forensic epidemiology and clinical management papers

17cross referenceMultipleflubromazolam synthesis history patent 1978 EP 00720295 results, 1 selected
selection rationale

Historical synthesis context

18literature searchPubMedbenzodiazepine opioid interaction synergistic respiratory depression pharmacodynamic5 results, 2 selected
selection rationale

Mechanism of opioid+benzodiazepine interaction relevant to flubromazolam lethality risk

19data extractionPubChem CID 21930924flubromazolam chemical identity1 result, 1 selected
selection rationale

Chemical identity verification completed

20document retrievalWebSearch / Federal Registerflubromazolam DEA Schedule I permanent 20265 results, 3 selected
selection rationale

Legal status confirmation

21document retrievalWHO ECDD 43rd—1 result, 1 selected
selection rationale

Key regulatory/scientific authority document

Research document (raw, unedited pipeline output)
# Research Output: Flubromazolam

**Substance:** Flubromazolam  
**PSX ID:** PSX-0195  
**Research Date:** 2026-04-26  
**Provenance ID:** 038de813-4fb5-44a6-87bb-033bb55e60e0

---

## Chemical Identity

**Verified via PubChem CID 21930924 [Ref 1 — database_lookup]:**

| Field | Value |
|---|---|
| PubChem CID | 21930924 |
| CAS Number | 612526-40-6 |
| IUPAC Name | 8-bromo-6-(2-fluorophenyl)-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine |
| Molecular Formula | C₁₇H₁₂BrFN₄ |
| Molecular Weight | 371.2 g/mol |
| SMILES | Cc1nnc2CN=C(c3ccccc3F)c4cc(Br)ccc4n12 |
| InChIKey | VXGSZBZQCBNUIP-UHFFFAOYSA-N |

**⚠️ Seed data flag:** The substance brief contained blank fields for SMILES, molecular formula, molecular weight, and InChIKey. All four values are now confirmed from PubChem CID 21930924. These should be added to the database.

Flubromazolam is a **triazolobenzodiazepine** — specifically the triazolo-analogue of flubromazepam, formed by the addition of a methyl-triazole ring fused at the 1,2-positions of the benzodiazepine scaffold. It bears a bromine substituent at the 8-position and a 2-fluorophenyl group at the 6-position, structural features that are shared with other high-potency triazolobenzodiazepines such as triazolam and alprazolam (Edinoff et al. 2022 [Ref 5]).

The compound is also referred to by the research designation **JYI-73** in some literature.

**Stereochemistry:** No chiral centers; no stereoisomers. The compound exists as a single structural form.

**Physical properties:** No published data on melting point or aqueous solubility in primary sources. High lipophilicity is implied by high plasma protein binding and large volume of distribution (Noble et al. 2017 [Ref 3]).

---

## Pharmacology

### Mechanism of Action

Flubromazolam acts as a **positive allosteric modulator (PAM) of the GABA-A receptor**, the primary mechanism shared by all benzodiazepines. Benzodiazepines bind to the extracellular α/γ subunit interface of pentameric GABA-A receptors, enhancing chloride ion conductance in response to GABA binding and thereby increasing inhibitory neurotransmission throughout the CNS (Zhu et al. 2022 [Ref 29]; Figg et al. 2026 [Ref 28]). This mechanism underlies flubromazolam's sedative, anxiolytic, muscle-relaxant, and amnestic effects.

No published substance-specific receptor binding data (Ki or EC₅₀ values at GABA-A or any other receptor) exist for flubromazolam in peer-reviewed literature. Waters et al. (2017 [Ref 24]) applied a quantitative structure-activity relationship (QSAR) model to predict GABA-A binding affinities of emerging designer benzodiazepines, concluding that **triazolobenzodiazepines as a class are predicted to be among the most potent** designer benzodiazepines — consistent with flubromazolam's reported low-dose efficacy. This remains a class-inference, not a substance-specific measurement.

**⚠️ Gap — Safety-critical:** No published Ki or EC₅₀ data for flubromazolam at GABA-A. Potency is inferred from structural class (triazolobenzodiazepine), one human self-experiment, and clinical case observations.

### Potency

Moosmann et al. (2015 [Ref 6]) noted that compounds like clonazolam and flubromazolam "can cause strong sedation and amnesia at oral doses as low as 0.5 mg," placing them among the highest-potency designer benzodiazepines. The WHO ECDD 43rd review (2020 [Ref 23]) specifically documented that a single 0.5 mg oral dose of flubromazolam produced strong sedative effects lasting **more than 10 hours** and caused **partial amnesia for more than 24 hours** — a duration consistent with a compound of high potency and long elimination half-life.

### Pharmacokinetics

The only published human pharmacokinetic data for flubromazolam comes from a single self-experiment by Huppertz, Moosmann & Auwärter (2018 [Ref 2]), in which one of the authors ingested a 0.5 mg oral dose:

- **Tmax:** ~8 hours post-ingestion  
- **Cmax:** ~8 ng/mL (serum; very low absolute concentration reflecting high potency)  
- **Terminal elimination half-life:** estimated 10–20 hours  
- **Urine detection:** parent compound detectable up to 6.5 days; mono-hydroxylated metabolite up to 8 days (LLOQ 0.1 ng/mL by LC-MS/MS)  
- **Hair detection:** detectable in hair samples collected 2 weeks post-ingestion (cmax 0.6 pg/mg)  
- **Immunoassay:** Negative in serum, positive in urine for up to 5 days post-ingestion

Noble et al. (2017 [Ref 3]) conducted in vitro metabolism studies in pooled human liver microsomes (pHLM) and recombinant CYP enzymes, adding equilibrium dialysis for plasma protein binding:

- **Primary metabolic enzymes:** CYP3A4 and CYP3A5 (hydroxylation at α- and/or 4-positions)
- **Phase II:** Glucuronidation of hydroxylated metabolites and direct N-glucuronidation of the parent compound by UGT enzymes
- **Predicted hepatic clearance (CL_H):** 0.42–0.43 mL/min/kg (low clearance; well-stirred and parallel-tube models concordant)
- **Protein binding:** High (quantified but not numerically specified in available abstract)
- **Key urine targets:** α-hydroxy-flubromazolam and its glucuronide; flubromazolam N-glucuronide

Huppertz et al. (2015 [Ref 22]) and Huppertz et al. (2018 [Ref 2]) report that detected metabolites in vivo include α-hydroxy-flubromazolam (main), α-hydroxy-flubromazolam glucuronide, and the N-glucuronide of the parent compound — in good agreement with the in vitro predictions.

Rat pharmacokinetic data (Canfield, Kisor & Sprague 2023 [Ref 4], Sprague-Dawley rats, 2 mg/kg SC): compared to alprazolam, flubromazolam showed **2-fold increases in both volume of distribution (VD) and clearance**. In contrast to flualprazolam (which showed a ~2× longer half-life), the half-life of flubromazolam in rats was **not significantly extended** relative to alprazolam, as the proportional increases in VD and CL cancelled in the t₁/₂ = 0.693 × VD/CL relationship. Despite this, the 2-fold increase in VD indicates greater body distribution and prolonged tissue exposure. The human half-life of 10–20 hours (Huppertz 2018 [Ref 2]) is broadly consistent with alprazolam's known human half-life range of ~6–26 hours.

**⚠️ Flag:** All human PK data derives from a **single-subject self-experiment** with a single dose (0.5 mg). Population variability in CYP3A4/5 activity, body weight, and co-medications could substantially alter PK parameters. CYP3A4/5 inhibitors (azole antifungals, ritonavir, grapefruit juice) would be expected to meaningfully increase flubromazolam exposure.

---

## History

### Synthesis and Patent History

Flubromazolam belongs to the triazolobenzodiazepine class developed primarily by pharmaceutical companies in the 1970s–1980s. Patent EP 0072029 B1 ("Triazolobenzazepines, process and intermediates for their preparation and medicines containing them," registered 1978, published 1986) is referenced in multiple secondary sources as the original patent covering flubromazolam and related compounds (web-retrieved; not independently API-verified). The compound was **never approved or licensed for therapeutic use** in any country.

Moosmann et al. (2015 [Ref 6]) noted that "nearly all of these compounds have been synthesized as drug candidates by pharmaceutical companies and their syntheses, as well as basic animal testing data, are described in the literature." This confirms the pharmaceutical candidate origin but the specific institutional source of flubromazolam synthesis could not be confirmed from API-accessible primary literature.

**⚠️ Gap:** Exact identity of original synthesizing institution and year of first synthesis requires confirmation from patent database searches (e.g., Espacenet or Google Patents for EP 0072029 B1). Cannot be independently verified from PubMed/OpenAlex.

### Emergence as a Novel Psychoactive Substance

Designer benzodiazepines as a class began appearing on online research chemical markets circa 2012 (Huppertz et al. 2018 [Ref 2]). Flubromazolam specifically was **first offered on internet markets from 2014** (Huppertz et al. 2018 [Ref 2]). The compound was first formally characterized in the peer-reviewed forensic toxicology literature by Huppertz, Bisel, Westphal, Franz, Auwärter & Moosmann (2015 [Ref 22]).

The pivotal public health alert was Moosmann, King & Auwärter's 2015 World Psychiatry letter (2015 [Ref 6]), which identified flubromazolam alongside clonazolam as posing particular risk due to their efficacy at "doses as low as 0.5 mg" — doses that are "extremely difficult to measure for users handling bulk materials, and tablets often vary greatly in the content of the active ingredient."

The first published clinical case report (Łukasik-Głębocka et al. 2015/2016 [Ref 1]) described a severe intoxication case with coma, hypotension, and rhabdomyolysis, establishing flubromazolam's life-threatening potential.

### Regulatory History

- **Switzerland:** Controlled by December 2015 (web-retrieved)
- **Sweden:** Scheduled by national authorities (EMCDDA noted, web-retrieved)
- **UK:** Class C, Schedule 1 under the Misuse of Drugs Act 1971, by amendment effective May 2017 (web-retrieved)
- **Australia:** Schedule 9 (prohibited substance) under federal law since approximately 2016 (web-retrieved, Freestone et al. 2026 [Ref 12])
- **United Nations:** CND 64th Session (June 2021) voted to place flubromazolam in **Schedule IV of the 1971 Convention on Psychotropic Substances** — prompting international treaty obligations for member states (Federal Register 2021-03268 [Ref 20])
- **USA:** Temporary Schedule I placement published Federal Register December 2022 (FR 2022-27278), extended July 2023 (FR 2023-15748 [Ref 21]); **permanent Schedule I** placement published Federal Register Vol. 91, No. 40, March 2, 2026, effective approximately April 1, 2026 (FR 2026-04112 [Ref 20])
- **Canada:** Controlled under Schedule IV of Canada's Controlled Drugs and Substances Act via the Benzodiazepines and Other Targeted Substances Regulations (web-retrieved)

---

## Subjective Effects

The following domains are drawn from the literature. No controlled dosing studies in human subjects beyond the single-researcher self-experiment exist.

**Primary effects documented (Edinoff et al. 2022 [Ref 5]; WHO ECDD 2020 [Ref 23]; Moosmann et al. 2015 [Ref 6]; Orsolini et al. 2020 [Ref 19]; El Balkhi et al. 2020 [Ref 13]):**

- **Sedation/Hypnosis:** Described as "heavy hypnosis and sedation" at typical recreational doses; the WHO ECDD documented sedative effects exceeding 10 hours at 0.5 mg (WHO ECDD 2020 [Ref 23])
- **Amnesia:** Partial amnesia lasting more than 24 hours at 0.5 mg (WHO ECDD 2020 [Ref 23]); described as "long-lasting amnesia" by recreational users (Edinoff et al. 2022 [Ref 5])
- **Anxiolysis:** Moderate anti-anxiety effects (Łukasik-Głębocka et al. 2016 [Ref 1])
- **Muscle relaxation:** Documented in case reports and user reports (Łukasik-Głębocka et al. 2016 [Ref 1]; Edinoff et al. 2022 [Ref 5])
- **Euphoria:** Reported by recreational users (Edinoff et al. 2022 [Ref 5])
- **Motor impairment:** Consistent with CNS depressant effects; confirmed in DUID evaluations (Papsun et al. 2023 [Ref 16])
- **Disinhibition and loss of control:** Reported in user accounts (Edinoff et al. 2022 [Ref 5]; Orsolini et al. 2020 [Ref 19])
- **Thought deceleration and disorganization:** Consistent with class effects; attributed in DUID studies to CNS depressant effects (Papsun et al. 2023 [Ref 16])
- **Delusions of sobriety / compulsive redosing:** Reported in community and WHO ECDD documentation (WHO ECDD 2020 [Ref 23])
- **Dreaming enhancement:** Sleep architecture effects are characteristic of benzodiazepines generally (Figg et al. 2026 [Ref 28])

**Duration:** One human self-experiment (0.5 mg oral) showed sedative effects lasting >10 hours (WHO ECDD 2020 [Ref 23]). The seed database value of 12–18 hours total duration is consistent with the 10–20-hour half-life (Huppertz et al. 2018 [Ref 2]) and is plausible; it cannot be independently verified from controlled study data. The extended duration arises from both the long half-life and high VD.

---

## Safety & Toxicity

### Acute Toxicity

**No published LD50 data** for flubromazolam in any species. **⚠️ Safety-critical flag — unverifiable from published sources.**

The WHO ECDD (2020 [Ref 23]) classified flubromazolam as having **no known therapeutic use** and documented both non-fatal intoxications requiring hospital admission and **fatal intoxications** associated with its use.

**First published case report:** Łukasik-Głębocka et al. (2016 [Ref 1]) described a severe intoxication with:
- Prolonged coma
- Hypotension
- Rhabdomyolysis
- The paper established flubromazolam as "life-threatening"

**⚠️ Note:** The seed data states "Acute: high; Chronic: high; Notes: low toxicity" — this appears internally contradictory. Based on the literature, the most accurate framing is: flubromazolam has relatively **low direct pharmacotoxicity** when used alone (consistent with the benzodiazepine class generally), but the **acute risk is high** due to the narrow margin between effective and toxic doses at microgram-range exposures, unpredictable tablet/powder dosing, and synergistic lethality with opioids and alcohol. This distinction should be preserved in the article.

### Fatality Data

- **Victoria, Australia 2018–2022:** Flubromazolam detected in 12 of 133 novel benzodiazepine-associated deaths; all deaths involved co-administration of at least one other CNS-active drug (Drummer et al. 2024 [Ref 31])
- **North Carolina 2020–2022:** Flubromazolam detected in counterfeit alprazolam, oxycodone, and hydrocodone pills associated with deaths; decedents ages 16–69 (Friederich et al. 2024 [Ref 32])
- **San Francisco 2019–2023:** Flubromazolam identified in designer benzodiazepine fatalities before bromazolam market dominance (Rodda 2024 [Ref 40])
- **England and Wales:** Flubromazolam co-detected in 48% of a 96-case bromazolam coronial series; implicated in polydrug deaths (Hikin et al. 2024 [Ref 41])
- **UK/US epidemiology:** Brunetti et al. (2021 [Ref 7]) identified flubromazolam as one of the top three designer benzodiazepines (alongside flualprazolam and etizolam) in adverse events, deaths, and DUID cases reported to UNODC 2019–April 2020
- **MMWR 2021 [Ref 34]:** Illicit benzodiazepine deaths (including flubromazolam) increased 519.6% from 2019 to mid-2020 in the US; 92.7% of all benzodiazepine deaths involved opioids

**Pattern across all death cases:** No published case establishes flubromazolam as the **sole** cause of death. All fatal cases involved co-administered CNS depressants (opioids, alcohol, or multiple benzodiazepines).

**Impaired driving as sole intoxicant:** The WHO ECDD (2020 [Ref 23]) and Papsun et al. (2023 [Ref 16]) document DUID cases where flubromazolam was the **sole identified intoxicant**, confirming substantial impairment from the drug alone.

### Polydrug Interaction Risk

The primary acute fatality mechanism is **synergistic respiratory depression** with opioids and other CNS depressants. Horsfall & Sprague (2017 [Ref 37]) described the combined opioid+benzodiazepine interaction as producing synergistic CNS and respiratory depression via co-located μ-opioid and GABA-A receptors in medullary respiratory centers. Xu et al. (2020 [Ref 38]) confirmed exacerbated respiratory depression (decreased PaO₂, increased PaCO₂) in opioid+BZD co-administration animal models.

In the US drug supply, flubromazolam has been found as an adulterant in unregulated opioid supplies (Laing et al. 2021 [Ref 14, 35]) and as a component of counterfeit prescription opioid and benzodiazepine pills (Friederich et al. 2024 [Ref 32]). The WHO ECDD (2020 [Ref 23]) specifically noted "the potential to increase unintentional opioid overdoses."

**⚠️ Safety-critical flag:** The combination of flubromazolam with opioids is particularly hazardous because:
1. Naloxone does not reverse benzodiazepine-mediated respiratory depression
2. Flubromazolam adulteration of illicit opioid supplies has been documented
3. The long duration of flubromazolam (~10–20h half-life) may exceed the duration of action of naloxone, requiring repeat dosing or hospital observation

---

## Harm Reduction

### Contraindications

No published controlled-study contraindications specific to flubromazolam. Class-level contraindications from benzodiazepine literature apply:

- **Opioid co-use:** FDA black box warning for all opioid+benzodiazepine combinations; synergistic respiratory depression (FDA/Figg et al. 2026 [Ref 28])
- **Alcohol:** CNS depressant synergy; documented in flubromazolam polydrug death cases
- **Other CNS depressants:** Including other benzodiazepines, Z-drugs, gabapentinoids, muscle relaxants, antipsychotics
- **Pregnancy and breastfeeding:** No published data for flubromazolam; class-level concerns with benzodiazepines (neonatal withdrawal syndrome)
- **Known benzodiazepine hypersensitivity**

**CYP3A4 inhibitors** (ketoconazole, itraconazole, ritonavir, clarithromycin, grapefruit juice) would be expected to substantially increase flubromazolam plasma concentrations, given CYP3A4/5 as the primary metabolic pathway (Noble et al. 2017 [Ref 3]).

### Testing and Identification

- **Immunoassay:** Flubromazolam shows high cross-reactivity in standard BZD immunoassays (CEDIA, EMIT II Plus, HEIA, KIMS II — Pettersson Bergstrand et al. 2017 [Ref 15]). Serum immunoassay may be negative while urine is positive (Huppertz et al. 2018 [Ref 2])
- **Confirmatory testing:** LC-MS/MS required for definitive identification and quantitation (Noble et al. 2017 [Ref 3]; Wu & Fu 2022 [Ref 27])
- **Hair analysis:** Detectable for at least 2 weeks post-single-dose (Huppertz et al. 2018 [Ref 2]); validated hair method exists (DeFreitas et al. 2022 [Ref 39])
- **Reagent testing:** Standard fentanyl test strips do not detect benzodiazepines; no widely validated point-of-care test for flubromazolam specifically (Laing et al. 2021 [Ref 14])

### Emergency Response

- **Flumazenil:** Can reverse benzodiazepine-induced sedation; however, Penninga et al. (2016 [Ref 36]) found flumazenil associated with 3.81× higher SAEs (supraventricular arrhythmia, seizures) vs placebo in benzodiazepine overdose. Systematic review (Farcas et al. 2025 [Ref 30]) notes pre-hospital IM flumazenil may be considered if naloxone-unresponsive coma with suspected BZD involvement. **Not recommended routinely** due to seizure precipitation risk in BZD-dependent individuals
- **Naloxone:** Does not reverse benzodiazepine respiratory depression; critical if opioid co-use suspected but will not address flubromazolam component
- **Supportive care:** Airway management, respiratory support, monitoring

---

## Tolerance & Dependence

### Tolerance

Rapid tolerance development is a consistently reported characteristic of flubromazolam. Edinoff et al. (2022 [Ref 5]) describe "rapid development of tolerance" as among the most common effects noted by recreational users. WHO ECDD (2020 [Ref 23]) documented online reports describing "rapid onset of tolerance" and noted this "suggests that taking increased doses and developing physical dependence is likely."

The molecular basis of BZD tolerance involves **downregulation of GABA-A receptor subunits** and compensatory sensitization of excitatory glutamatergic systems (Navarrete et al. 2026 [Ref 43]; Figg et al. 2026 [Ref 28]).

The seed database value of **"within a couple of days of continuous use"** for tolerance buildup is consistent with reported literature patterns for high-potency benzodiazepines, but is not directly cited from a flubromazolam-specific clinical study.

### Dependence

Flubromazolam is described as "extremely physically and psychologically addictive" in the seed data. This characterization is supported by:

- WHO ECDD (2020 [Ref 23]): Multiple online sources describe severe withdrawal symptoms and "loss of control over use"
- Butler et al. (2025 [Ref 11]): Case report of a male in his early 20s presenting with seizure following **abrupt cessation** of illicit benzodiazepines including flubromazolam; symptom-based management required because **no established long-acting BZD equivalence dose exists for flubromazolam**
- Edinoff et al. (2022 [Ref 5]): "Severe withdrawals" documented in recreational users

The WHO ECDD (2020 [Ref 23]) described withdrawal symptoms from online sources as including:
- Muscle aches
- Sleep disturbances
- Severe anxiety and panic attacks
- Dissociative symptoms
- Perceptual distortions
- Cramping
- Chills and vomiting
- **Risk of seizures** (potentially life-threatening)

**⚠️ Safety-critical flag:** No published controlled studies exist examining flubromazolam dependence potential. All dependence/withdrawal data derives from user reports, case reports, and class-level inference. The absence of an established benzodiazepine equivalence conversion dose (Butler et al. 2025 [Ref 11]) creates a clinical management gap.

### Cross-Tolerance

Cross-tolerance with all benzodiazepines and related GABAergic drugs (Z-drugs, alcohol, barbiturates) is expected from mechanism. The seed data value of "cross-tolerances: benzodiazepines" is consistent with class pharmacology.

### Tolerance Reset

The seed database value of **full reset at 10.5 days** (i.e., 10–20× the expected half-life, consistent with receptor upregulation timelines) is plausible for a compound with a 10–20-hour half-life and is consistent with classical BZD tolerance kinetics, but is not directly cited from a flubromazolam-specific study. It relies on structural analogy and general BZD tolerance data.

---

## Interactions

### Opioids (Critical)

Documented in multiple death series. Mechanism: synergistic respiratory depression via co-located μ-opioid and GABA-A receptor effects in medullary respiratory centers (Horsfall & Sprague 2017 [Ref 37]; Xu et al. 2020 [Ref 38]). Flubromazolam's long half-life means respiratory depression may persist well beyond opioid effects or naloxone duration. MMWR data (Liu et al. 2021 [Ref 34]): 92.7% of BZD deaths involved opioids; illicitly manufactured fentanyls predominant.

### Alcohol

CNS and respiratory depressant synergy. Documented in polydrug death cases. No specific pharmacokinetic interaction study for flubromazolam + alcohol.

### Other CNS Depressants

Gabapentinoids, other benzodiazepines, antipsychotics, tricyclic antidepressants, muscle relaxants, and sedating antihistamines: additive/synergistic CNS depression expected. In 48% of bromazolam coronial cases in England/Wales, flubromazolam co-occurred with at least one other designer benzodiazepine (Hikin et al. 2024 [Ref 41]).

### CYP3A4/5 Inhibitors

Because flubromazolam is primarily metabolized by CYP3A4 and CYP3A5 (Noble et al. 2017 [Ref 3]), strong CYP3A4 inhibitors (itraconazole, ketoconazole, voriconazole, ritonavir, clarithromycin, grapefruit) would be expected to substantially increase flubromazolam plasma concentrations and prolong its duration of action. This has not been tested in published studies but is strongly implied by the metabolic pathway data.

### Kratom / Mitragynine

Butler et al. (2025 [Ref 11]) specifically noted that kratom's inhibition of benzodiazepine metabolism was a complicating factor in withdrawal management for a patient using flubromazolam among other substances. This suggests a pharmacokinetic interaction via shared CYP enzyme pathways, though specific data are absent.

**⚠️ Flag:** No flubromazolam-specific drug interaction studies exist. All interaction data is either anecdotal (from death series), mechanistic inference from CYP enzyme data, or extrapolated from class-level benzodiazepine interaction research.

---

## Legal Status

| Jurisdiction | Status | Schedule/Class | Date |
|---|---|---|---|
| United States | Controlled | Schedule I (permanent) | ~April 1, 2026 |
| United States (prior) | Controlled | Schedule I (temporary) | December 2022 – March 2026 |
| United Kingdom | Controlled | Class C, Schedule 1 | May 2017 |
| Australia | Controlled | Schedule 9 (Prohibited) | ~2016 |
| Canada | Controlled | Schedule IV (CDSA) | N/A (grouped) |
| Sweden | Controlled | Scheduled | ~2015 |
| Switzerland | Controlled | Illegal | December 2015 |
| UN International | Controlled | 1971 Convention Schedule IV | June 2021 (CND 64th Session) |

Sources: Federal Register publications [Ref 20, 21]; web-retrieved national regulatory records; WHO ECDD 43rd [Ref 23].

**Analog Act applicability (pre-2023 USA):** The DEA press release (September 2023) and Federal Register filings indicate that prior to temporary scheduling in December 2022, flubromazolam was potentially subject to the Controlled Substances Analogue Enforcement Act as a structural analogue of scheduled benzodiazepines, though enforcement was inconsistent (Moosmann et al. 2015 [Ref 6]).

---

## Clinical Trials

**Search of ClinicalTrials.gov returned zero results for flubromazolam.** No clinical trials have been registered for this compound. This is consistent with its status as an unregistered research chemical with no approved medical use anywhere in the world.

---

## Community Feedback Analysis

No community feedback was submitted in Part A2 of the brief.

---

## Gaps & Flags

### Safety-Critical Values Not Confirmed by Published Sources

1. **LD50:** No published LD50 data in any species. Cannot confirm acute lethality threshold. ⚠️ FLAG
2. **Binding affinity (Ki/EC₅₀):** No published receptor binding data. Potency inferred from class (QSAR) and clinical observations. ⚠️ FLAG
3. **Dose ranges (threshold/light/common/strong/heavy):** Seed DB values are in micrograms (50–400+ μg range) and are consistent with the 0.5 mg pharmacologically effective dose reported by Huppertz et al. (2018 [Ref 2]) and the ~0.5 mg effective dose noted by Moosmann et al. (2015 [Ref 6]). However, these specific breakpoints are community-consensus-derived, not from controlled dose-escalation studies. The generation agent should propose these as community-derived values with note that formal dose-response data are absent.
4. **Benzodiazepine equivalence conversion:** No published equivalence dose exists (Butler et al. 2025 [Ref 11]). Clinical management of withdrawal requires symptom-based approach. ⚠️ FLAG

### Data Quality Concerns

5. **Human PK — single subject only:** All human PK data (Huppertz et al. 2018 [Ref 2]) derives from a single researcher self-experiment with 0.5 mg. Population PK parameters are unknown. ⚠️ FLAG
6. **Seed data internal contradiction:** "Toxicity data: Acute: high; Chronic: high; Notes: low toxicity" — this is contradictory as written. Recommended resolution: "low intrinsic toxicity; high acute/chronic risk." ⚠️ FLAG
7. **Rat vs human half-life:** Rat data (Canfield 2023 [Ref 4]) showed no significant half-life change vs alprazolam; human data (Huppertz 2018 [Ref 2]) suggests 10–20h half-life broadly similar to alprazolam range. These are consistent but the rat model may not fully translate.

### Missing Chemical Data (Now Confirmed)

8. **SMILES, formula, MW, InChIKey were all blank in the seed database.** Confirmed values:
   - Formula: C₁₇H₁₂BrFN₄
   - MW: 371.2 g/mol
   - SMILES: Cc1nnc2CN=C(c3ccccc3F)c4cc(Br)ccc4n12
   - InChIKey: VXGSZBZQCBNUIP-UHFFFAOYSA-N
   - PubChem CID: 21930924

### Historical/Synthesis Gaps

9. **Original synthesis attribution:** Patent EP 0072029 B1 (1978) referenced in secondary sources as the original synthesis, but could not be directly verified from PubMed/Crossref APIs. The specific inventor and institution require patent database verification.
10. **No bioavailability data:** No published oral bioavailability studies for flubromazolam.
11. **No formal pharmacodynamic studies:** No controlled human studies examining onset, peak effect, or dose-response relationships.

### Interactions

12. **All interaction data is mechanistic or case-series derived.** No controlled pharmacokinetic interaction studies published. CYP3A4 inhibitor interactions are strongly mechanistically implied but unconfirmed experimentally.

### Dependence/Withdrawal

13. **No published formal dependence/tolerance studies** (animal or human). All data is from user reports, online community, case series, and class inference. The generation agent should clearly label dependence severity claims as user-report-derived pending formal study.